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ABSTRACT 
 
 
SUMOylation is an evolutionary conserved post-translational regulatory mechanism 
involving the covalent attachment of a Small Ubiquitin-like MOdifier (SUMO) to 
target proteins in reactions catalyzed by E1, E2 and E3 enzymes. The consequences of 
protein SUMOylation are varied; it can affect protein localization, create new 
interaction surfaces, exclude others, regulate transcription factor activity, and protect 
proteins from destruction. Loss of SUMOylation is not compatible with life, as 
knock-out of the only E2 enzyme (Ubc9) leads to embryonic lethality in mice. 
SUMOylation is possible but less specific and efficient in the absence of E3 enzymes, 
of which the protein inhibitors of activated STAT (PIAS) family is the most widely 
studied. In mammals, there are three conjugatable SUMO paralogs of which SUMO-1 
differs from SUMO2/3 the most and lacks the ability to form (poly)SUMO chains. 
SUMO2/3 are encoded by two separate genes, but differ only by three amino acids 
leading to many overlapping functions. 
 
The purpose of this thesis was to study the in vivo functions of SUMOylation by using 
knock-out animal models. PIAS2 is an E3 enzyme highly expressed in testis and 
involved in androgen signaling. A Pias2 null mouse line was generated and found to 
be fertile and viable. Loss of Pias2 led to a decrease in testicular weight and sperm 
count and increase in apoptotic cells in the seminiferous tubules. However, the sperm 
was qualitatively normal, potentially due to compensation by other PIAS proteins. 
When Sumo1 was knocked out by targeted disruption, the mice were born in normal 
Mendelian ratios, and were viable and fertile. At least in the case of Ran GTPase-
activating protein 1 (RanGAP1), the most heavily SUMO-1 modified protein, lack of 
SUMO-1 resulted in its SUMOylation by SUMO-2/3. This compensatory mechanism, 
however, was not reflected in the mRNA levels. In testis, SUMO-1 was localized to a 
nuclear structure called sex vesicle present in pachytene spermatocytes. SUMO-2/3 
was also present there, and the structure was able to form in the absence of SUMO-1.  
 
The phenotypes of the Sumo1 null and wild-type mice did not differ under normal 
laboratory conditions. However, when the mice were challenged with 
lipopolysaccharide (LPS), a bacterial antigen, Sumo1 null mice developed a more 
pronounced acute phase response in liver due to inefficient transrepressive function of 
Abstract 
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liver receptor homolog 1 (LRH-1) leading to more efficient removal of repressive 
factors from inflammatory gene promoters. Another nuclear receptor, liver X receptor 
(LXR), required SUMO-2/3 modification to function properly testifying that SUMO 
paralogs can partly but not in all cases compensate for each other. Another example 
found in this study where Sumo1 function cannot be compensated for was 
adipogenesis. Adipogenesis is highly dependent on the functions of peroxisome 
proliferator-activated receptor (PPAR) γ. It was found that, contrary to previous 
reports, gene activation functions of PPARγ are compromised in the absence of 
SUMO-1, as shown by inefficient transactivation of a luciferase reporter in Sumo1 
null cells and incomplete response of Sumo1 knock-out mice to rosiglitazone, a 
PPARγ agonist. Furthermore, embryonic fibroblasts and mesenchymal stem cells of 
Sumo1 null mice and SUMO-1-depleted preadipocytes differentiated less efficiently 
into adipocytes, further demonstrating the importance of SUMO-1 in the activation 
functions of PPARγ. When Sumo1 null mice were challenged with a high-fat diet, 
they gained less weight than their wild-type littermates due to a limited expansion of 
white adipose tissue. The results show that SUMO-1 is important for the activation 
functions of PPARγ either via modification of PPARγ or a coregulatory protein. 
 
Taken together, the results of this thesis show that the SUMOylation pathway has 
many redundant functions. However, this study identified physiological phenomena 
where the lack of Pias2 or Sumo1 could not be compensated for in vivo. 
Yhteenveto 
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YHTEENVETO 
 
 
SUMOlaatio on evoluutiossa säilynyt translaationjälkeinen säätelymekanismi, jossa 
E1-, E2- ja E3-entsyymit liittävät kovalentilla sidoksella kohdeproteiineihin pienen 
Small Ubiquitin-like MOdifier (SUMO) -proteiinin. SUMOlaation vaikutukset ovat 
moninaiset, sillä se pystyy vaikuttamaan proteiinien sijaintiin, luomaan uusia 
kosketuspintoja tai peittämään niitä, säätelemään transkriptiotekijöiden aktiivisuutta 
ja suojaamaan proteiineja hajotukselta. SUMOlaatio on elämälle välttämätön, minkä 
osoittaa ainoan E2-entsyymin suhteen poistogeenisen hiiren alkionkehityksen 
aikainen letaali ilmiasu. SUMOlaatio on mahdollinen mutta epäspesifisempi ja 
tehottomampi ilman E3-entsyymejä, joista tunnetuimpia ovat protein inhibitors of 
activated STAT (PIAS) -perheen proteiinit. Nisäkkäillä on kolme SUMO-paralogia, 
joista SUMO-1 eroaa eniten SUMO2/3:sta, eikä pysty muodostamaan SUMO-ketjuja. 
SUMO2/3, joita koodittaa kaksi erillistä geeniä, eroavat toisistaan vain kolmen 
aminohapon osalta, mikä johtaa moniin päällekkäisiin toimintoihin. 
 
Tämän väitöskirjatutkimuksen tavoite oli tutkia poistogeenisten eläinmallien avulla 
SUMOlaation in vivo -vaikutuksia. PIAS2 on miessukupuolihormonien signalointiin 
vaikuttava E3-entsyymi, joka ilmenee runsaana kiveksessä. Tutkimusta varten luotiin 
Pias2-poistogeeninen hiirimalli, joka osoittautui elin- ja lisääntymiskykyiseksi, 
vaikka Pias2-geenin puuttuminen johti pienentyneeseen kivesten painoon ja 
siittiöntuotantoon sekä ohjelmoidun solukuoleman lisääntymiseen siementiehyissä. 
Hiirten siemenneste oli kuitenkin laadullisesti normaalia johtuen todennäköisesti 
muiden PIAS-proteiinien kompensaatiosta. Sumo1-geenin kohdennettu poistaminen 
johti niinikään elinkelpoisiin ja lisääntymiskykyisiin hiiriin, jotka syntyivät 
normaaleissa mendeelisissä suhteissa.  Tutkimuksissa havaittiin, että Ran GTPase-
activating protein (RanGAP) 1, joka on solujen voimakkaimmin SUMO-1:llä 
muokattu proteiini, muokkautuu SUMO2/3:lla SUMO-1-proteiinin puuttuessa. Tämä 
kompensaatiomekanismi ei kuitenkaan heijastunut RNA-tasolle. Kiveksessä SUMO-
1-proteiinia on erityisesti sukupuolivesikkelissä, joka on pakyteenispermatosyyteissä 
ilmenevä tuman rakenne. SUMO2/3 sijaitsee samassa rakenteessa, eikä SUMO-1:n 
puuttuminen estä sen muodostumista. 
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Normaaleissa laboratorio-olosuhteissa Sumo1-poistogeenisten hiirten ja villityypin 
hiirten välillä ei havaittu eroja. Sen sijaan hiirten altistaminen bakteerien pinta-
antigeeni lipopolysakkaridille (LPS) johti voimakkaampaan akuutin faasin 
tulehdusreaktioon maksassa Sumo1-poistogeenisillä hiirillä johtuen Liver Receptor 
Homolog (LRH) 1 -tumareseptorin heikommasta transrepressiokyvystä, jolloin 
geenien luentaa hillitsevät tekijät poistuvat tulehdusgeenien promoottoreilta 
nopeammin kuin normaalisti. Toinen tumareseptori, liver X receptor (LXR), 
puolestaan vaati SUMO-2/3-modifikaation normaaliin toimintaansa. Nämä tulokset 
osoittivat, etteivät SUMO-paralogit voi kompensoida kaikkia toistensa tehtäviä. 
Toinen tutkimuksen paljastama esimerkki, jossa Sumo1:n puuttumista ei voida 
korvata, on rasvasolujen erilaistuminen, joka on voimakkaasti riippuvainen 
peroxisome proliferator-activated receptor (PPAR) γ -tumareseptorista. PPARγ:n 
havaittiin aktivoivan geenejä heikommin Sumo1-geenin puuttuessa – aiemman tiedon 
vastaisesti. Tämän osoittivat solukokeissa lusiferaasiraportoijageenin heikompi luenta 
Sumo1-poistogeenisissä soluissa ja Sumo1-poistogeenisten hiirten heikompi vaste 
PPARγ:n agonistille, rosiglitatsonille. Lisäksi Sumo1-poistogeeniset hiiren 
embryonaaliset fibroblastit ja mesenkymaaliset kantasolut sekä Sumo1-geeniä heikosti 
ilmentävät preadiposyytit erilaistuivat huonommin rasvasoluiksi viitaten SUMO-1:n 
olevan tärkeä PPARγ:n aktivaatiolle. Kun Sumo1-poistogeeniset hiiret laitettiin 
rasvaiselle ruokavaliolle, ne lihoivat vähemmän kuin villityypin hiiret johtuen niiden 
valkoisen rasvakudoksen heikosta laajenemisesta, mikä näkyy rasvasolujen 
vähäisyytenä ja pienuutena. Nämä tulokset viittavat siihen, että joko PPARγ tai sen 
kanssa vuorovaikuttava säätelijäproteiini tarvitsee SUMO-1-proteiinia toimiakseen 
normaalisti.  
 
Tämän tutkimuksen tulokset osoittavat, että vaikka SUMOlaatioketjun proteiineilla on 
monia päällekkäisiä tehtäviä, tässä tutkimuksessa saatiin selville fysiologisia ilmiöitä, 
joissa Pias2- tai Sumo1-geenien puuttumista ei voitu kompensoida. 
Original publications 
 9 
ORIGINAL PUBLICATIONS 
 
 
I. Santti H, Mikkonen L, Anand A, Hirvonen-Santti S, Toppari J, Panhuysen M, 
Vauti F, Perera M, Corte G, Wurst W, Jänne OA, Palvimo JJ 2005. Disruption 
of the murine PIASx gene results in reduced testis weight. J Mol Endocrinol 
34:645-654 
 
II. Zhang F-P*, Mikkonen L*, Toppari J, Palvimo JJ, Thesleff I, Jänne OA 2008 
Sumo1 function is dispensable in normal mouse development. Mol Cell Biol 
28:5381-5390  
 
III. Venteclef N, Jakobsson T, Ehrlund A, Damdimopoulos A, Mikkonen L, Ellis 
E, Nilsson LM, Parini P, Jänne OA, Gustafsson JÅ, Steffensen K, Treuter E 
2009 GPS2-dependent corepressor/SUMO pathways govern anti-
inflammatory actions of LRH-1 and LXRβ in the hepatic acute phase 
response. Genes Dev 24:381-395 
 
IV. Mikkonen L, Hirvonen J, Jänne OA 2012 SUMO-1 regulates body weight and 
adipogenesis via PPARγ in male and female mice. Endocrinology 154:698-
708 
 
* Equal contribution 
 
The above articles are referred to in the text as publications I–IV. In addition, some 
unpublished results are presented. 
 
The manuscript of the publication I was included in the thesis by Dr. Henrikki Santti. 
Publication III was included in the theses of Dr. Thomas Jakobsson and Dr. Anna 
Ehrlund in Sweden.  
 
The original publications are reproduced with permission of the copyright holders. 
Abbreviations 
 10 
ABBREVIATIONS 
 
AF  activation function 
AP  activator protein 
APR  acute phase response 
AR  androgen receptor 
BAT  brown adipose tissue 
BLM  Bloom syndrome protein 
BRCA1 breast cancer 1, early onset 
CBP  CREB-binding protein 
C/EBP  CCAAT-enhancer-binding protein  
ChIP  chromatin immunoprecipitation 
CLP  cleft lip and palate 
CRP  C-reactive protein 
Cys  cysteine 
DAX-1 dosage sensitive sex reversal-adrenal hypoplasia congenital gene on 
the X chromosome, gene 1  
DAXX death-domain associated protein 
DBD  DNA-binding domain 
DDR  DNA damage response 
DeSI  deSUMOylating isopeptidase 
Dex  dexamethasone 
dpc  day(s) post conception 
DSB  double strand break 
ER  estrogen receptor 
ESC  embryonic stem cells 
FA  fatty acid 
FEN   flap structure-specific endonuclease 
GR  glucocorticoid receptor 
GRE  glucocorticoid response element 
HD  Huntington’s disease 
HDAC  histone deacetylase 
HIF  hypoxia-inducible factor 
HIPK  homeodomain-interacting protein kinase 
HR  homologous recombination 
HRE  hormone response element 
Htt  Huntingtin 
IFN  interferon 
Ik-Bα  NF-κB inhibitor alpha 
IKK  inhibitor of kappa-B kinase 
IL  interleukin 
IRF  interferon regulatory factor 
KO  knock-out 
LBD  ligand binding domain 
LXR  liver X receptor  
LPS  lipopolysaccharide 
LRH  liver receptor homolog 
LXRE  LXR response elements 
Lys  lysine 
MEF  mouse embryonic fibroblast 
MSC  mesenchymal stem cell 
MYF  myogenic factor 
NB  nuclear body 
NCoR  nuclear receptor corepressor 
NDSM  negatively charged amino acid-dependent SUMO motif 
NEMO NF-κB essential modulator 
NFAT  nuclear factor of activated T-cells 
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NF-κB  nuclear factor κ-B 
NR  nuclear receptor 
NTD  amino terminal domain 
P53BP  p53-binding protein 
PCNA  proliferating cell nuclear antigen 
PDSM  phosphorylation-dependent SUMO motif 
PGC  peroxisome proliferator-activated receptor-γ coactivator 
PIAS  protein inhibitors of activated STAT 
PML  promyelocytic leukemia protein 
Pol II  RNA Polymerase II 
PPAR  peroxisome proliferator-activated receptor  
PRDM  PR domain containing 
PRR  post-replication repair 
qRT-PCR quantitative real-time PCR 
RanBP  Ran-binding protein 
RanGAP Ran GTPase-activating protein  
RCT  reverse cholesterol transport 
RIP140 receptor interacting protein 140 
RNF  ring finger protein 
ROR  RAR-related orphan receptor 
ROS  reactive oxidative species 
RXR  retinoid X receptor  
SAA  serum amyloid A 
SEM  standard error of mean 
SENP  sentrin/SUMO-specific protease 
Ser  serine 
SHP  small heterodimer partner 
SIM  SUMO-interacting motif 
SMRT  silencing mediator for retinoid and thyroid receptors 
SRY  sex-determining region of the Y chromosome 
STAT  signal transducers and activators of transcription 
STUbL SUMO-targeted ubiquitin ligase 
SUMO  small ubiquitin-like modifier 
TF  transcription factor 
TBP  TATA-box binding protein 
TDG  thymine-DNA glycosylase 
TGF  transforming growth factor 
TLR  toll-like receptor 
TNF  tumor necrosis factor 
TOPORS topoisomerase I-binding, arginine/serine rich 
TR  thyroid hormone receptor 
TZD  thiazolidinedione 
UBL  ubiquitin-like protein 
UCP  uncoupling protein 
WAT  white adipose tissue 
WT  wild-type 
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INTRODUCTION 
 
 
 
Hormones are molecules that are secreted into the blood stream and that act in target 
cells via specific receptors. When the hormones are lipophilic, such as steroid 
hormones or intermediates of fat metabolism, they diffuse through the cell membrane 
to reach their cognate receptors, which belong to the superfamily of nuclear receptors 
(Mangelsdorf et al. 1995). The hormone-occupied nuclear receptors then affect the 
expression of target genes by either inhibiting or activating their transcription and act 
in concert with coregulator complexes the assembly of which is influenced by several 
factors among other post-translational modifications (PTMs) (Anbalagan et al. 2012).  
 
PTMs come in many flavors consisting of a covalent addition of a molecule, such as 
phosphorylation, or a small protein, which is the case in SUMOylation. SUMOylation 
refers to modification of substrate proteins with a Small Ubiquitin-like MOdifier, 
changing the conformation of the target protein allosterically or creating new 
interaction surfaces (Yeh 2009). Most nuclear receptors are SUMOylated leading in 
many instances to decreased gene activation function (Treuter and Venteclef 2011; 
Anbalagan et al. 2012).  
 
Nuclear receptors (NRs) control many essential functions of the body, including 
development, reproduction, inflammation and metabolism. They have been targeted 
for the treatment of many diseases and not always without side effects (Gronemeyer 
et al. 2004). As every tissue has its own combination of nuclear receptors, 
coregulators and other modifying proteins, the development of more specific drugs 
requires thorough dissection of the underlying mechanisms by which the actions of 
these receptors are exerted. The functions of SUMOylation in different physiological 
contexts involving NR action form the basis of this thesis. 
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REVIEW OF THE LITERATURE 
 
1. Nuclear receptors as regulators of transcription 
 
DNA contains instructions to all proteins present in any cell of the organism. 
However, cells and tissues are different in the selection of genes turned on and off 
leading to a different mixture of proteins in each cell type varying with time and 
responses to intracellular and extracellular signals. An important checkpoint is the 
regulation of transcription, where the amount of regulatory RNA or mRNA coding for 
a specific protein is kept under control. mRNA stability, alternative splicing, 
translation, and protein activity and stability are further tightly regulated. Therefore, 
the dogma ”gene-mRNA-protein” and the definition of a gene have been redefined by 
recognizing RNA as an important end product (Djebali et al. 2012). 
 
1.1 Transcription factors and their coregulators 
 
Approximately three-quarters of DNA is transcribed into different kinds of RNA 
products in eukaryotic cells, but the transcriptome of different cell types comprises 
39% of the genome on the average (Djebali et al. 2012). How some areas of the 
genome are transcribed while other remain silent involves regulation of chromatin 
accessibility and the mixture of transcription factors and their coregulators present in 
each cell. Minimal requirements for a protein-coding gene to be transcribed are RNA 
polymerase II (Pol II) on the minimal promoter along with the general transcription 
machinery. Previously, it was considered a hallmark of transcriptional activation that, 
when a gene is turned on, transcription factor (TF) IID, via its subunit TATA-box 
binding protein (TBP), binds a conserved DNA sequence composed of T and A. 
Recently, however, a 50-base-pair footprint was identified to define the site of 
transcript origination within thousands of human promoters with TBP occupancy in 
the center of the region but, surprisingly, lacking the classical TATA-box (Neph et al. 
2012). Other general transcription factors along with Pol II assemble onto the 
promoter to form a transcription initiation complex. In vivo, where DNA is wrapped 
around histones to form nucleosomes, DNA needs to be unwound with the help of 
additional proteins, and the whole process of transcription initiation includes more 
than 100 proteins. The Mediator complex bridges the interaction between Pol II, 
Review of the literature 
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general TFs, other TFs and coactivators/corepressors together with chromatin-
modifying enzymes, chromatin-remodeling complexes and histone-modifying genes 
(Fig. 1). The definition of a gene not only includes the transcribed DNA sequence but 
all the regulatory sequences often situated far away from the transcription start site 
(TSS). These regulatory DNAs have been mapped using the DNAse I hypersensitive 
sites as markers of cis-regulatory elements, as occupancy of TFs creates a gap in place 
of a canonical nucleosome that is available for enzyme cleavage (Thurman et al. 
2012). 
 
TFs are proteins that directly bind to DNA, and they usually have a specific DNA-
binding motif such as helix-turn-helix, zinc finger or leucine zipper. TFs may bind to 
DNA alone or more often as a combination forming a delicately regulated hierarchical 
network (Gerstein et al. 2012). Recently, ChIP (chromatin immunoprecipitation) -on-
chip and ChIP-sequencing techniques have revolutionized the TF field by allowing 
the identification of all DNA-binding sites ("cistromes") of a given protein or TF in a 
given cell or tissue type. TFs interact with coregulators, which have multiple 
functions. They may act as bridging factors that make the TF, the Mediator, the 
general transcription factors and ultimately the Pol II a stable complex, allowing the 
release of Pol II from the pre-initiation complex and turning on the elongation phase 
(Nechaev et al. 2011). In addition, TFs attract other proteins with chromatin and 
histone modifying properties, thus affecting the availability of DNA to yet other 
proteins. PTMs  – discussed in detail below – are crucial in defining the combinations 
of different proteins and even switching a coactivator into a corepressor in a specific 
context.  
Review of the literature 
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Figure 1. Overview of transcriptional regulation. Adapted from Ecker et al. 2012. 
 
 
1.2 The nuclear receptor superfamily 
 
A very special class of TFs are the nuclear receptors (NRs). Nuclear receptors are a 
large family of homologous proteins comprising receptors for hormones (steroids and 
thyroid hormones), retinoic acid and fatty acids, as well as orphan receptors for which 
ligands have not been identified (Gronemeyer et al. 2004; Mangelsdorf et al. 1995). 
There are 48 NR genes in humans encoding proteins that regulate diverse vital 
processes of life ranging from development and reproduction to metabolism and body 
homeostasis (Bertrand et al. 2004), and they have been classified based on their 
molecular properties (www.nursa.org). Class I NRs are receptors for steroid hormones 
such as androgen receptor (AR). Class II receptors have non-steroidal lipophilic 
ligands such as thyroid hormone receptor (TR) and peroxisome proliferator-activated 
receptors (PPARs). Class III receptors either do not have an identified ligand or have 
a closed ligand-binding pocket forming the group of orphan receptors. NRs have a 
Chromosome 
DNase I 
hypersensitive 
sites  
Nucleosome Histone 
Long-range 
chromatin 
interactions 
DNA 
methylation 
Chromatin 
modifications 
Transcription 
machinery 
Transcription-factor 
binding sites 
Transcription-factor 
Long-range regulatory 
elements 
Promoter 
architecture 
Transcribed region 
Protein-coding 
and non-coding 
transcripts 
DNA 
Review of the literature 
 16 
characteristic structure comprising an amino-terminal domain (NTD), a DNA-binding 
domain (DBD), a hinge region and a carboxy-terminal ligand-binding domain (LBD).  
 
The NTD (A/B domain) varies considerably between different NRs and contains a 
transactivation domain 1 (AF-1) interacting with coregulators (Wärnmark et al. 2003). 
AF-1 may work ligand-independently as a regulator of transcription or it may be 
affected by ligand binding of the LBD via intramolecular interaction, as is the case 
with the androgen receptor (AR) (Langley et al. 1995). The DBD recognizes the 
cognate hormone response elements (HREs) on DNA with its two conserved zinc 
finger domains each characterized by four highly conserved cysteine (Cys) residues 
coordinating a zinc ion (Freedman et al. 1988). The DBD contains two α-helices the 
first of which binds directly to the major groove of DNA, whereas the C-terminal 
extension of the DBD – highly variable between NRs – interacts with sequences 
flanking the core HRE and adding specificity to DNA binding (Melvin et al. 2004). 
DAX1 (dosage sensitive sex reversal-adrenal hypoplasia congenital gene on the X 
chromosome, gene 1; NR0B1) and SHP1 (small heterodimer partner; NR0B2) are 
exceptions to the general NR structure, in that they lack DBD and function through 
protein-protein interactions (Seol et al. 1996; Zanaria et al. 1994). The hinge region 
between DBD and LBD brings spatial flexibility to the receptors, participates in 
coregulator binding, forms part of the bipartite nuclear localization signal and is 
subject to PTMs (Pourcet et al. 2010). The C-terminal LBD varies to some extent 
among the NRs to allow ligand-specific responses and also contains the ligand-
dependent activation function (AF-2) domain (Gronemeyer et al. 2004). The domain 
is formed by 12 helices, the helix 12 being crucial in moving over the ligand-binding 
pocket when a ligand is present allowing some coregulators to dispatch and others to 
bind. Some NRs, such as NURR1, have such a small ligand-binding pocket that they 
hardly can bind any ligand and may thus remain true orphans (Wang et al. 2003). In 
addition to binding coregulators in a ligand-dependent manner, this domain also 
contains part of the nuclear localization signal and is essential in NR dimerization.  
 
The ligands of NRs are lipophilic. In the absence of ligand, NRs reside in the 
cytoplasm or nucleus. The ligands diffuse passively from the blood stream through 
the cell membrane reaching the receptor inside the cell. Alternatively, the ligand may 
be produced within the target cell. Some reports show that this may not be the only 
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mode of function for certain NRs as cell membrane bound NRs have been detected 
(Madak-Erdogan et al. 2008). However, it is well established that the nuclear 
functions related to gene regulation are the principal mode of action of this protein 
family.  
 
 
 
 
Figure 2. Schematic structure of NRs. NRs share a common structure containing an 
N-terminal region (A/B), a DNA-binding domain (C), a hinge region (D), a ligand-
binding domain (E) and a C-terminal domain (F). 
 
 
 
 
1.3 Transcriptional activation and repression by NRs 
 
There is a growing list of over 350 NR coregulators involved in NR-mediated gene 
activation and repression (O’Malley et al. 2008; Lonard et al. 2012). In the absence of 
an agonist, many class II NRs (e.g., PPARγ) reside in the nucleus along with 
corepressors, such as NCoR or SMRT, actively repressing target genes, NCoR/SMRT 
being part of multiprotein complexes comprising enzymes such as histone 
deacetylases silencing the chromatin nearby. Upon ligand binding, PPARγ 
heterodimerizes with the promiscuous retinoid X receptor (RXR), corepressors are 
changed into coactivators, and this leads to activation of target genes. Class I NRs 
(e.g., AR) are in the cytoplasm when not bound to a ligand. Ligand binding liberates 
the receptor from heat shock proteins, allowing it to homodimerize and through the 
nuclear localization signal move to the nucleus, where it binds to the cognate HREs 
along with coactivators or corepressors depending on the context, turning target genes 
on or off, respectively. A common mechanism for ligand-induced conformational 
change is the movement of helix 12 against the LBD, creating a surface for interaction 
with coregulators containing an LxxLL (where L is leucine and x is any amino acid) 
(Heery et al. 1997). For instance, the p160 family of coregulators (SRC-1–3) and 
RIP140 (receptor interacting protein 140), an important coregulator in the adipose 
N C DNA Ligand 
A/B C D E F 
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tissue, all contain an LxxLL motif. The AF-2 situated in the LBD is required for 
ligand-dependent activation in steroid receptors (Danielian et al. 1992).  
 
NRs bind to DNA as monomers, homodimers (e.g., AR) or heterodimers (e.g., 
PPARγ/RXR). HREs for the class I receptors (steroid receptors) are mainly inverted 
hexanucleotide repeats with three base pair spacing (IR3) (Cotnoir-White et al. 2011). 
Class II receptors typically heterodimerize with RXR and recognize HREs with direct 
repeats with a varied spacing (DR1–5) while class III receptors mainly function as 
monomers. DNA has to be accessible to TFs before they can bind to their response 
elements. In recent years, pioneer factors making the chromatin environment 
accessible for NRs have been under attention. Such a pioneer factor for estrogen 
receptor (ER) and AR is FoxA1 (Carroll et al. 2005; Sahu et al. 2011). NR binding 
sites reside typically far away from transcription start sites (TSSs) upstream or 
downstream, in inter- or intragenic regions (Carroll et al. 2005; Sahu et al. 2011; 
Lefterova et al. 2008; Nielsen et al. 2008; So et al. 2007). 
 
Mechanisms of transcriptional activation are better understood than transcriptional 
repression. For a long time, it was thought that binding of an agonist simply produces 
an interaction surface for coactivators, whereas binding of an antagonist or in the case 
of class II receptors, absence of ligand, involves corepressor binding leading to 
transcriptional repression. However, this view is a gross underestimation of the 
complexity of the regulatory mechanisms, since binding of an agonist may as well 
lead to transcriptional repression (negative regulation). ChIP-seq experiments 
combined with global gene expression analyses have exponentially shed light into 
these mechanisms. Transcriptional repression has several mechanisms. One is the still 
disputed existence of negative response elements where DNA changes the 
conformation of the ligand-bound receptor into one that cannot positively regulate the 
target gene (Sakai et al. 1988). It seems that the traditional coactivator/corepressor 
division needs to be revised, because a protein may function as either coregulator 
depending on the cell-type, promoter and status of its PTMs, as demonstrated by 
LSD1 (lysine-specific demethylase 1) acting mostly as a corepressor. However, it 
may also act as a coactivator on promoters where histone 3 is phosphorylated 
(Metzger et al. 2010). Approximately half of the differentially regulated genes are 
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downregulated when a NR ligand is added, but some of this regulation may be 
indirect (Kininis et al. 2008). 
 
 
 
Figure 3. Simplified model of transrepression showing NF-κB on a promoter of an 
inflammatory gene. The presence of GR stabilizes corepressor complexes, inhibits 
their clearance from the promoter and interferes with the recruitment of coactivators. 
Adapted from Glass and Saijo 2010. 
 
 
A special form of transcriptional repression is the tethering of NRs onto repressor 
complexes and their stabilization without their direct loading onto the DNA, a 
phenomenon referred to as ”transrepression” as opposed to cis-acting regulation (Fig. 
3). Transrepression was first found for glucocorticoid receptor (GR) that can inhibit 
the functions of both activator protein 1 (AP1) and nuclear factor-κB (NF-κB) on a 
wide range of promoters. It was shown in macrophages that upon stimulation by LPS 
acting via toll-like receptor (TLR) 4, GR loading sites on DNA were devoid of 
glucocorticoid response elements but contained interferon regulatory factor (IRF) 3-
binding motifs and that dexamethasone (Dex), a GR ligand, disrupted the interaction 
between p65, a subunit of NF-κB, and IRF3 or PTEFb that are needed for full 
activation of NF-κB target genes (Ogawa et al. 2005; Luecke et al. 2005). Later, it 
was found that other mechanisms exist for other NRs and they complement each other 
in a gene- and cell-specific manner. Peroxisome proliferator-activated receptor 
(PPAR) γ and liver X receptors (LXR) have been shown to repress inflammation in 
macrophages and liver (Pascual et al. 2005; Ghisletti et al. 2007; Blaschke et al. 
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2006). Transrepression has been shown to inhibit the expression of inflammatory 
genes governed not only by AP-1 and NF-κB but nuclear factor of activated T-cells 
(NFAT) and signal transducers and activators of transcription (STAT). Innate 
inflammation is a non-specific response against pathogens and plays a role in the low-
grade inflammation aggravating several diseases including metabolic syndrome. 
Therefore, ligand-dependent inhibition of inflammation by NRs has opened new 
therapeutic opportunities. 
 
1.4 PPARs 
 
PPARs form a family of three members – PPARα (NR1C1), PPARβ/δ (NR1C2) and 
PPARγ (NR1C3) – belonging to the class II NRs and forming heterodimers with 
RXR. They are widely expressed and regulate lipid and carbohydrate metabolism, cell 
proliferation, vascular biology, tissue repair and inflammation (Wahli et al. 2012). 
PPARs have an isotype-specific but partially overlapping expression profiles, and 
they all are involved in anti-inflammatory mechanisms alleviating the deleterious 
effects of the low-grade inflammation present in metabolic syndrome. They use fatty 
acid (FA) derivatives as endogenous ligands and may therefore be considered as 
nutrient sensors (Forman et al. 1997).  
 
PPARα is highly expressed in tissues with active β-oxidation (FA oxidation) and 
dense mitochondrial content such as brown adipose tissue (BAT), liver, kidney and 
heart (Escher et al. 2001). PPARα is the major regulator of the hepatic response to 
fasting, inducing expression of genes involved in FA catabolism and ketogenesis 
(Kersten et al. 1999). Fibrates are synthetic ligands of PPARα successfully used to 
treat hyperlipidemias. 
 
PPARβ/δ is more ubiquitously expressed but is the predominantly expressed PPAR 
isoform in skeletal and cardiac muscle as well as pancreatic β-cells (Escher et al. 
2001). Activation of PPARβ/δ in muscle results in increase in oxidative capacity of 
muscle cells and an increase in the number of type I myofibers reminiscent of 
physical training (Wang et al. 2004; Tanaka et al. 2003). 
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PPARγ is the master regulator of adipogenesis and a coordinator of whole-body 
insulin sensitivity (Tontonoz et al. 1994). Like other PPARs, it is considered a 
nutrient sensor having several FAs as ligands at a micromolar range (Forman et al. 
1997; Krey et al. 1997). Synthetic PPARγ ligands – the thiazolidinediones (TZDs) – 
have been widely used to improve glucose tolerance in diabetics (Cariou et al. 2012). 
However, this class of drugs has also deleterious effects limiting their clinical use. 
One of these effects is a marked weight gain due to increased adiposity (Cariou et al. 
2012; Nesto et al. 2004). PPARγ is transcribed as two isoforms from alternative 
promoters, PPARγ1 and PPARγ2, the latter of which is almost exclusively expressed 
in adipocytes. PPARγ2-specific knock-out mouse models have shown that PPARγ1 
can compensate to some extent for the absence of PPARγ2 in vivo. However, mouse 
embryonic fibroblasts (MEFs) from these mice differentiated poorly into adipocytes 
under cell culture conditions (Medina-Gomez et al. 2005; Zhang et al. 2004). Besides 
being the most important TF in adipose tissue, PPARγ has important functions in 
other cell types such as macrophages, where it limits the inflammatory response and 
protects the body from atherosclerosis and insulin resistance. The binding sites of 
PPARγ on chromatin are highly cell type-specific reflecting the chromatin context 
and available coregulators (Lefterova et al. 2010). PPARγ is heavily influenced by 
PTMs, discussed in more detail in chapter 3.1. 
 
1.5 LXR 
 
Liver X receptors (LXR) α and β (NR1H3 and NR1H2, respectively) are adopted 
orphan NRs of the class II. They use oxysterols – oxidized cholesterol metabolites – 
as natural ligands and are encoded by two separate genes (Janowski et al. 1996). In 
addition to being physiological regulators of lipid and cholesterol metabolism in liver, 
these receptors are involved in anti-inflammation in a fashion similar to PPARs. 
LXRs bind to DNA through LXR response elements (LXREs) consisting of a direct 
repeat with a spacing of four nucleotides (DR4), but they may also regulate gene 
transcription through tethering onto other TFs without a direct contact to DNA. It 
seems that ligand binding is an important determinant of LXR function, as it increases 
substantially the number of LXR-binding events on chromatin of murine liver and 
human macrophages (Boergesen et al. 2012; Pehkonen et al. 2012). LXRβ is 
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ubiquitously expressed, whereas LXRα is more specifically expressed in liver, 
adipose tissue and intestine (www.nursa.com).  
 
The key effects of LXR activation are related to the control of cholesterol metabolism 
and lipogenesis in liver (Peet et al. 1998; Repa et al. 2000; Boergesen et al. 2012). It 
is also important in reverse cholesterol transport (RCT) through upregulation of the 
cholesterol transporters ABCG1 and ABCA1 in macrophages (Naik et al. 2006). RCT 
is responsible for removing cholesterol away from the tissues and ultimately out of 
the body via bile, thus protecting the body from atherosclerosis. In addition to direct 
regulation of gene transcription programs, LXRs are also involved in transrepression 
of inflammatory genes. Therefore, pharmacological activation of LXR would be an 
attractive therapeutic target in treating metabolic diseases, but so far the side effects 
related to increased lipogenesis, elevation of blood triglyceride levels and 
neurological symptoms have prevented clinical use of LXR agonists in human 
patients (Bensinger et al. 2008; Katz et al. 2009). 
 
1.6 LRH-1 
 
Liver receptor homolog-1 (LRH-1; NR5A2) is a metabolic sensor involved in early 
development, bile acid synthesis, cholesterol metabolism and steroidogenesis (Fayard 
et al. 2004; Lazarus et al. 2012). It is mainly expressed in embryonic stem cells, liver, 
intestine, pancreas and ovary (www.nursa.com). Although initially identified as an 
orphan NR exhibiting constitutive activity and binding to DNA as a monomer, the 
ligands of LRH-1 now include endogenous phospholipids and synthetic compounds 
(Sablin et al. 2003; Ortlund et al. 2005; Lazarus et al. 2012). However, PTMs and 
interaction with coregulators and other NRs seem to be more important in regulating 
its activity. For instance, physical interaction of LRH-1 with the orphan receptor 
small heterodimer partner (SHP) or DAX-1 leads to a decrease in the transcriptional 
activation of LRH-1 (Ortlund et al. 2005; Sablin et al. 2008).  
 
The physiological role of LRH-1 in liver is related to RCT and excretion of 
cholesterol metabolites into the bile (Lee et al. 2008; Chong et al. 2012). Notably, 
LRH-1 positively regulates CYP7A1, the key enzyme in bile acid production (Nitta et 
al. 1999). In the intestine, LRH-1 is involved in regulation of enterohepatic circulation 
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and inhibition of bile acid absorption (Chen et al. 2003). In early development, LRH-
1 has a crucial role in inducing the expression of Oct1, one of the four genes required 
to maintain pluripotency and may even replace it (Gu et al. 2005; Heng et al. 2010).   
 
2. SUMOylation pathway 
 
PTMs include phosphorylation, acetylation, ubiquitination, to name but a few. 
Ubiquitin was the first protein-based modification described and soon other ubiquitin-
like proteins (UBLs) were found, all conjugated to lysine (Lys) side chains of target 
proteins (Kerscher et al. 2006). The classical function of ubiquitin is to tag proteins 
for 26S proteasomal degradation via Lys48-linked polyubiquitin chains, although new 
functions are beginning to emerge, mainly involving monoubiquitination or different 
chain formation (Sadowski et al. 2012). The various ubiquitin modifications are 
reminiscent of a code recognized by a large machinery and leading to multiple 
outcomes in cells (Komander and Rape 2012). Isolated in 1975 (Goldstein et al. 
1975), ubiquitin was later found to have relatives based on sequence similarity. The 
family of UBLs now encompasses nearly 20 proteins that all harbor a similar 3D 
structure, but are surprisingly diverse in function (van der Veen and Ploegh 2012). A 
common function for all UBLs is to alter the interaction properties of target proteins, 
either by promoting or inhibiting their binding to other proteins.  
 
2.1 Sumo1-4 
 
Small Ubiquitin-like MOdifier (SUMO) is an 11-kDa protein structurally very close 
to ubiquitin. Yeast only has one type of SUMO (Smt3), but metazoans, including 
mice and humans, have four SUMO paralogs each encoded by its own gene, Sumo1-
4. SUMO-1 shares the amino acid sequence by 50% with SUMO-2 and -3, whose 
mature forms differ by three N-terminal amino acid residues from each other. These 
three amino acids reside very close to the SUMO consensus sequence involved in 
chain formation, and the part that is cleaved from the precursor protein is also 
different and slightly longer in SUMO-3 compared to SUMO-2. Therefore, the small 
differences are likely to contribute to dissimilar functions of the two proteins although 
most studies have referred to them as SUMO-2/3, and not much is known about the 
specific functions of these paralogs. The most obvious difference between SUMO-1 
Review of the literature 
 24 
and SUMO-2/3 is that SUMO-2/3 form (poly)SUMO chains, whereas SUMO-1 is 
either used as a monoSUMO modification or as the last SUMO of a chain (Matic et 
al. 2008; Wilkinson et al. 2010). Sumo1-3 are ubiquitously expressed in all stages of 
development and in all cell types (Wilkinson and Henley 2010). Most of SUMO-1 is 
attached to target proteins, whereas unconjugated SUMO-2/3 is suggested to serve as 
a reserve for stress situations (Saitoh and Hinchey 2000). 
 
Sumo4 is expressed in spleen, lymph nodes and kidney (Guo et al. 2004). Because of 
a proline residue close to the diglycine motif essential for the activation step discussed 
below, SUMO-4 cannot be processed in vivo and, therefore, is not considered to be 
involved in PTMs (Owerbach et al. 2005). Also, lacking introns, Sumo4 may be a 
pseudogene, although a polymorphism in its sequence has been associated with 
autoimmune diseases such as type I diabetes (Bohren et al. 2004; Guo et al. 2004). 
 
The SUMOylation process is catalyzed by activating (E1), conjugating (E2) and 
ligating (E3) enzymes, analogous to the ubiquitin pathway (Fig. 4). However, where 
the ubiquitin system has a wide array of enzymes, the SUMOylation pathway has 
only one E1 enzyme (SAE1/SAE2 heterodimer in mammals, also known as 
AOS1/UBA2), one E2 enzyme (UBC9) and a handful of E3 enzymes. All SUMO 
proteins are translated as immature precursors that are activated by C-terminal 
cleavage revealing a Gly-Gly-motif (Gly for glycine). This step is carried out by 
sentrin-specific proteases (SENPs), the same enzymes that remove SUMO from target 
proteins, discussed below. Then the E1 enzyme (heterodimer SAE1/SAE2) adenylates 
SUMO and transfers it to the catalytic Cys of SAE2 forming a thioesther bond 
between SUMO and SAE2 (activation), followed by transfer of SUMO further to the 
catalytic Cys of UBC9 by a thioesther bond. UBC9 can then catalyze the conjugation 
of SUMO to the acceptor Lys independently of E3 enzymes (Bernier-Villamor et al. 
2002). However, in most cases SUMOylation is more efficient in the presence of E3 
enzymes (Tatham et al. 2003).  
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Figure 4. The SUMOylation pathway. Adapted from Wang and Dasso 2009. (S= 
SUMO). 
 
 
2.2 E3 enzymes  
 
Although possible with mere E1 and E2 enzymes, SUMOylation becomes clearly 
more efficient and more specific when catalyzed by E3 enzymes (Gareau and Lima 
2010). The SUMO pathway has five classes of E3 enzymes: SIZ/PIAS family, Ran-
binding protein (RanBP) 2, Polycomb 2 homologue (PC2), histone deacetylase 
(HDAC) 4 and TOPORS (topoisomerase I-binding, arginine/serine rich). RanBP can 
be found as a very stable complex throughout the cell cycle together with 
SUMOylated RanGAP1, the most heavily SUMOylated protein in the cell, and recent 
evidence suggests that it is the multiprotein complex composed of SUMOylated 
RanGAP1, UBC9 and RanBP2 that acts as a functional SUMO E3 ligase (Matunis et 
al. 1996; Werner et al. 2012). PC2 acts as an E3 ligase towards a handful of substrates 
(Kagey et al. 2003; Long et al. 2005; Wotton and Merrill 2007), while HDAC4 only 
has a few known substrates such as MEF2 (Zhao et al. 2005). The substrates of 
TOPORS include p53 and many chromatin-modifying proteins (Weger et al. 2005; 
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Pungaliya et al. 2007). Interestingly, TOPORS may also act as a ubiquitin E3 ligase, 
working thus at the interface of the two pathways regulated by phosphorylation 
(Rajendra et al. 2004; Park et al. 2008). In some instances, it is possible that the 
substrate functions as its own E3 ligase through intramolecular interactions (Quimby 
et al. 2006). 
 
The first E3 enzymes identified were the PIAS orthologs in yeast, the Siz proteins 
(Johnson and Gupta 2001). Although PIAS proteins were originally identified as 
protein inhibitors of activated STAT, it was soon discovered that their functions were 
not limited to STAT signaling (Chung et al. 1997; Liu et al. 1998). They are now 
considered the most widely functioning group of E3 enzymes acting towards a large 
array of targets, and they are found ubiquitously in vertebrates. The human and 
murine PIAS proteins are encoded by four genes: Pias1, Pias2 (Piasx), Pias3, Pias4 
(Piasy) of which Pias2 and Pias4 are highly expressed in testis. Pias2 encodes two 
proteins through alternative splicing, PIASxα (ARIP3) and PIASxβ (Miz1). 
 
All PIAS proteins have a conserved structure including an N-terminal SAP (SAF-
A/B, Acinus and PIAS) domain involved in DNA and transcription factor binding 
(Okubo et al. 2004). The PINIT domain is involved in nuclear localization and the C-
terminal S/T domain varies between the members (Duval et al. 2003). The domains 
linked to SUMOylation are the SP (Siz/PIAS) -RING domain and the SIM (SUMO-
interacting motif). Many RING-containing proteins act as E3 enzymes of the 
ubiquitin pathway, and the SP-RING has been thought to have a related mode of 
function. The SIM domain is essential for recognition of SUMO (see below). It is 
interesting to note that PIAS proteins may have complex effects on TFs as 
demonstrated by studies on AR. SUMOylation of AR leads to transcriptional 
repression (Poukka et al. 2000). However, PIAS1 that mediates this modification may 
also act as a coactivator for AR, and this coactivator function is dependent both on 
AR SUMOylation sites and SP-RING domain of PIAS1 (Kotaja et al. 2000; Kotaja et 
al. 2002). Thus, the current view is that the PIAS proteins have different context-
dependent functions some of which are related to SUMOylation. It is also interesting 
to note that the PIAS proteins themselves are substrates for SUMOylation and other 
PTMs, adding yet another layer to their regulation. 
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2.3 SENPs  
 
SUMOylation is a highly reversible process. Only a small fraction of target proteins 
are SUMOylated at any one moment, and the cell responds to different stimuli with a 
rapid shift between on and off states. The first deSUMOylating enzyme identified was 
Ulp1 in yeast, and the mammalian deSUMOylating enzymes were identified on the 
basis of the sequence similarity with the yeast protein (Li and Hochstrasser 1999). 
The mammalian cell has six sentrin/SUMO-specific proteases (SENPs) of which 
SENP1 and SENP2 appear to be broader in their substrate specificity than the rest 
(SENP3, -5, -6 and -7). They do not discriminate between the SUMO paralogs and 
function as both C-terminal hydrolases (forming the mature form of SUMO) and 
isopeptidases (deSUMOylating target proteins). SENP3 and SENP5-7 function as 
isopeptidases only and prefer SUMO2/3 as substrates. Recently, a new class of 
deSUMOylating enzymes was described consisting of two mammalian proteins DeSI 
(deSUMOylating isopeptidase) 1 and DeSI-2 (Shin et al. 2012). DeSI-1 and -2 have a 
wide tissue distribution in mice and, unlike nuclear SENPs, are also present in the 
cytoplasm (Shin et al. 2012). Furthermore, Wss1, belonging to yet another class of 
proteases (Wss1p-like metalloproteases) was suggested to have SUMO-dependent 
isopeptidase activity in yeast, but direct evidence is still missing (Mullen et al. 2010). 
 
2.4 Consensus motifs for SUMO conjugation and recognition 
 
The carboxyl group of the C-terminal glycine in SUMO is covalently attached to the 
ε-amino group of a lysine residue in the target proteins at a consensus ψKXE site, 
where ψ is a large hydrophobic amino acid, K is lysine, X is any amino acid and E is 
glutamic acid (Anckar et al. 2007). SUMO-2 and -3 contain this consensus sequence 
through which the (poly)SUMO chains are formed. Extensions of the SUMO 
consensus site include phosphorylation-dependent SUMO motifs (PDSM) and 
negatively charged amino acid-dependent SUMO motifs (NDSMs) (Hietakangas et al. 
2006; Yang et al. 2006). However, not all consensus sequences are actually 
SUMOylated and other SUMOylation sites not fitting the above consensus sequence 
have been observed (Matic et al. 2010; Pichler et al. 2005). Therefore, more studies 
are needed to confirm the in silico predicted SUMOylation sites. This is going to be a 
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time- and labor-consuming task, since even the in vitro and in vivo mechanisms may 
differ significantly (Lee et al. 2011).  
 
Proteins recognizing SUMO contain a SIM. While SUMOylation consensus sequence 
is responsible for the covalent modification of the substrate protein, SIMs mediate the 
non-covalent interactions of SUMO and other proteins (Kerscher 2007). A SIM motif 
is suggested to contain a hydrophobic core sequence next to acidic residues flanked 
by two serine (Ser) residues, although the requirement for the Ser-residues has been 
disputed (Minty et al. 2000; Song et al. 2004). In many cases, a SIM is required in the 
SUMO substrate to mediate the SUMOylation by bringing SUMO and the substrate 
together before the covalent bonding. This has been shown at least with TDG 
(thymine-DNA glycosylase), DAXX (death-domain associated protein) and BLM 
(Bloom syndrome protein) (Takahashi et al. 2005; Lin et al. 2006; Zhu et al. 2008). 
To some other proteins, SUMOylation may take place without a SIM domain, 
although SIM may be important for another function. This is the case for PML 
(promyelocytic leukemia protein), a protein essential for the formation of a 
subnuclear structure, the PML nuclear body (NB). PML lacking the SIM sequence 
may be SUMOylated and this SUMOylation is required for the PML NB formation, 
but dispersion of the NB requires an intact SIM (Duprez et al. 1998; Maroui et al. 
2012). The PML NBs are thought to be the SUMOylation hotspots of the cell, since 
most of the proteins localized to these structures are SUMOylated (Lallemand-
Breitenbach et al. 2010). SIMs are also present in many proteins of the SUMOylation 
machinery including the E1 and many of the E3 enzymes (Minty et al. 2000; 
Stehmeier et al. 2009). 
 
2.5 Crosstalk with other modifications  
 
SUMOylation can be seen as part of a post-translational code where one modification 
precedes another or where SUMOylation inhibits another modification. The well-
known example of the latter includes the SUMOylation of Iκ-Bα (nuclear factor -κB 
[NF-κB] inhibitor alpha) (Desterro et al. 1998). SUMOylation of Iκ-Bα leads to 
stabilization of the protein by preventing its ubiquitination and subsequent 
proteasomal degradation. PCNA (proliferating cell nuclear antigen) has been found to 
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be modified in a similar fashion by either SUMO or ubiquitin at the same Lys residue, 
leading to selection of different pathways in DNA replication stress depending of the 
modification (Hoege et al. 2002).  
 
Functional consequences of SUMOylation include creation of new interaction 
surfaces or masking the existing ones. The effector proteins recognizing SUMO 
modification may have the ability to modify the target protein further. This is evident 
in the class of SUMO-targeted ubiquitin ligases (STUbLs), first identified in yeast, 
which changed the whole SUMO paradigm from competitor of ubiquitin into 
enhancer of ubiquitin chain formation and therefore promoter of proteasomal 
degradation in some cases. The proteins harbor ubiquitin E3 ligase activity and one or 
many SIMs recognizing SUMO non-covalently. The STUbLs identified so far are the 
mammalian RNF4 (ring finger protein 4) corresponding to Slx5/Slx8 in 
Saccharomyces cerevisiae (Sun et al. 2007; Xie et al. 2007). The functions of 
STUbLs include regulation of transcription factors, DNA damage and arsenic-induced 
degradation of the PML NB (Wang et al. 2011; Galanty et al. 2012; Tatham et al. 
2008).  
 
The aforementioned extension of the SUMO consensus sequence, the PDSM, 
provides an example of the interplay between phosphorylation and SUMOylation. In 
the sequence ψKXEXXSP, the regulatory proline-directed Ser residue (SP) is 
phosphorylated prior to SUMO conjugation in an E2-dependent manner (Hietakangas 
et al. 2006; Mohideen et al. 2009). Furthermore, when the same Ser residue is 
dephosphorylated in neurons, the Lys is acetylated instead of being SUMOylated, 
known as a SUMOylation-acetylation switch (Shalizi et al. 2006). The SUMOylation-
acetylation switch has been shown in phosphorylation-independent sites as well 
(Stankovic-Valentin et al. 2007), and SUMO itself is sometimes modified by 
acetylation leading to diminished SUMO-SIM interactions (Ullman et al. 2012). An 
example of multiple layers of the PTM code is the human FEN1 (flap structure-
specific endonuclease 1) that is post-translationally modified by phosphorylation, 
leading to SUMOylation by SUMO-3. Both of these modifications are needed for 
ubiquitylation leading to protein degradation (Guo et al. 2012). A defect in any of 
these modifications results in accumulation of FEN1 and a delay in the cell cycle.  
 
Review of the literature 
 30 
3. Functions of SUMOylation 
 
SUMOylation is essential to life, because knock-out mice lacking the only E2, Ubc9, 
are embryonically lethal at the early postimplantation stage (Nacerddine et al. 2005). 
Zebrafish devoid of all three SUMO paralogs is embryonically lethal, but the presence 
of any SUMO protein restored the phenotype (Yuan et al. 2010). Invertebrates have 
only one SUMO, SMT3. In yeast, mutation of SMT3 or UBC9 leads to arrests in cell 
cycle, and C. elegans devoid of its only SUMO gene results in abnormal 
embryogenesis (Seufert et al. 1995; Dieckhoff et al. 2004; Broday et al. 2004). On the 
other hand, too much of SUMO may be harmful as shown by a study in C. elegans 
(Rytinki et al. 2012). The first identified SUMO substrate was RanGAP1 involved in 
nuclear transport and soon a plethora of SUMO targets were identified, making 
SUMOylation one of the established regulators of cellular functions (Matunis et al. 
1996; Mahajan et al. 1997). Animal models related to SUMOylation are summarized 
in Table 1. 
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Table 1. Animal models related to the SUMO pathway 
 
????? ??????? ????? ?????????? ??????????
?????? ??? ????? ????????????????????? ?????????????????????
? ??? ????? ?????????????????????????????????? ??????????????????????
??????
??????
??????
??????????????????
??????????
????????????????????? ?????????????????
????? ??? ?????
?
?????????????????????????????
?????????????????
???????????????????????
? ???????????????
??????
???????????????????????????????
????????????????????????????
????????????????
?????? ??? ????? ?????????????????? ????????? ????????????????
?????? ??? ????? ?????????????????????? ?????????????????
? ?
?
???????????????????????? ?????????????????
????????????????????????????????? ?????????????????
??????
??????
?????????? ????? ???????????????????????????????????? ?????????????????
??????? ??? ????? ?????????????????????????
??????????????????????????????????
???????????????????
??????????????????????
?????? ??? ????? ??????????????????????? ????????????
???????????????????????????????????
??????????????????
? ??????????????????
????????? ?????????
???????????????????????????????
???????????
??????????????????????
?????? ??? ????? ???????????????????????????????
????????
?????????????????
? ?????????????????
???????????????
??????
????????????????????????????????
????????
????????????????
?????? ??? ????? ???????????????????? ????????? ?????
????????????????
????????????
 
 
3.1 Regulation of transcription 
 
SUMOylation was initially associated only with inhibition of transcription (Gill 
2005). However, as the number of modified TFs increased, it became clear that 
SUMOylation regulates transcription in a context-dependent manner with multiple 
mechanisms leading to positive or negative regulation of transcription.  
 
Modification of transcription factors. A lot of TFs and their coregulators have been 
shown to be subject to SUMOylation, which can affect a TF's ability to bind DNA, 
alter the stability of a coregulator complex or attract/exclude proteins with enzymatic 
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activity (Lyst and Stancheva 2007). The repression by SUMO is thought to result 
from the recruitment of chromatin-modifying enzymes such as HDACs (Yang and 
Sharrocks 2004; Girdwood et al. 2003). In some cases, SUMOylation leads to 
sequestration of the TF to a nuclear compartment not involved with transcriptional 
activation (Sachdev et al. 2001). However, SUMOylation may also lead to 
transcriptional activation, and this has been shown at least with p53, RORα (RAR-
related orphan receptor alpha) and TCF-4 (transcription factor 4) (Gostissa et al. 
1999; Hwang et al. 2009; Ihara et al. 2005).  
 
Many NRs are targets for SUMOylation (Table 2). The consequences of NR 
SUMOylation are varied and to make the matters more complex, PTMs often form a 
combination of modifications with PPARγ serving as a good example. The function 
of PPARγ is modulated by several PTMs, such as phosphorylation, ubiquitination and 
SUMOylation (van Beekum et al. 2009). Phosphorylation of Ser112 results in reduced 
transcriptional activity of PPARγ, which, in turn, is required for Lys107 
SUMOylation leading to inhibition of PPARγ transactivation function in vitro (Hu et 
al. 1996; Ohshima et al. 2004; Yamashita et al. 2004; Floyd and Stephens 2004). 
Moreover, the knock-in mice with a Ser112A (A for alanine) mutation are protected 
from insulin resistance on high-fat diet (Rangwala et al. 2003). In transrepression, 
discussed in more detail below, ligand-induced SUMOylation of Lys395 stabilizes the 
repressor complex in macrophages (Pascual et al. 2005). The anti-diabetic actions of 
PPARγ are possible to achieve even ligand-independently by blocking the 
phosphorylation of Ser273, a modification more often observed in obese than lean 
individuals (Choi et al. 2011). The ligand-induced poly-ubiquitination (the exact site 
of which is not known) appears to be important in negative regulation of the receptor 
through proteasomal degradation (Hauser et al. 2000).  
 
Modification of chromatin and histones. Chromatin is composed of DNA wrapped 
around histones and may be turned active or inactive by modifications involving the 
DNA or the histones. SUMOylation of all four major histone types was found to 
result in gene repression in S. cerevisiae (Nathan et al. 2006). In human cells, histone 
H4 is SUMOylated resulting in gene silencing through recruitment of HDACs (Shiio 
and Eisenman 2003). SUMOylation of H1 and H3 has also been observed, but 
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functional consequences of this modification are unknown (Matafora et al. 2009). 
Although SUMOylation has been associated with gene repression, a recent paper 
describes the occupation of SUMO-1 on HeLa cell chromatin in a genome-wide 
manner as being involved with active housekeeping genes and associated with active 
chromatin marks (Liu et al. 2012b). A similar result was already found in yeast, where 
ChIP experiments detected SUMO-modified proteins on actively transcribed genes 
and on promoters of inducible genes upon gene activation. However, silencing of 
UBC9 resulted paradoxically to even higher induction of these genes, implying that 
multiple mechanisms exist (Rosonina et al. 2010). Thus, SUMOylation regulates 
chromatin in many different ways and is not a simple repressive mark as previously 
thought.  
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Table 2. Effect of SUMOylation on NR function. Adapted from Treuter and 
Venteclef 2011. 
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3.2 Regulation of inflammation 
 
Inflammation is a complex response of the body against pathogens, damaged cells or 
irritants. Deregulation of inflammation leads to inflammatory diseases such as 
rheumatoid arthritis or atherosclerosis and therefore, inflammatory responses are 
tightly regulated. Inflammation can be local involving migration of monocytes into 
the inflamed tissue via increased vascular permeability mediated by local cytokines. 
In more severe inflammatory responses, the liver produces a variety of acute phase 
proteins including SAA (serum amyloid A), CRP (C-reactive protein) and 
haptoglobin. CRP is widely used in the clinic to assess the severity of bacterial 
infection or degree of inflammation.  
 
The first hints that SUMOylation plays a part in the regulation of inflammation came 
from the seminal paper describing the SUMOylation of Iκ-Bα in vitro (Desterro et al. 
1998). A key player in inflammation is NF-κB that regulates positively a set of 
inflammatory genes. Normally, NF-κB is kept out of the nucleus by Iκ-Bα, which, 
upon inflammatory signaling by e.g. TNFα (tumor necrosis factor alpha), is 
phosphorylated by IKK (inhibitor of kappa-B kinase) leading to its modification by 
ubiquitin and subsequent degradation by the proteasomal system. However, 
SUMOylation of Iκ-Bα protects the protein from ubiquitination at the same Lys 
residue stabilizing the protein and leading to retention of NF-κB in the cytoplasm. 
This led to a hypothesis that the main function of SUMOylation is the protection of 
proteins from degradation, but later studies have shown that this is rarely the case. As 
discussed above, modification of a substrate by SUMO may even lead to its 
degradation via STUbLs (Sun et al. 2007). Recently, SUMOylation was shown to 
negatively regulate the NF-κB in the nucleus via the RelA subunit as well (Liu et al. 
2012a), confirming SUMO as the inhibitor of the NF-κB pathway in inflammation. It 
is important to note that the NF-κB may also be activated by genotoxic stress and in 
this setting (nucleus-to-cytoplasm signaling), SUMOylation is involved in the 
activation of the pathway via NEMO (NF-κB essential modulator), the IKKγ 
regulatory subunit of the IKK complex (Huang et al. 2003; Mabb et al. 2006). NF-κB 
is at the crossroads of several pathways linking apoptotic and inflammatory signals 
together highlighting the importance of its proper regulation. 
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SUMOylation has turned out to be an essential layer in the regulation of inflammation 
by stabilization of NRs with corepressors on the promoters of inflammatory genes 
(transrepression). Lipopolysaccharide (LPS) is a bacterial antigen recognized by 
TLR4 on the cell surface of macrophages resulting in the activation of innate 
immunity towards pathogens. Activation of the TLR4 results in derepression of the 
inflammatory genes by active clearance of the nuclear receptor corepressor complexes 
containing NCoR or SMRT as well as TBLR1, TBL1, HDAC3, from the promoters. 
Most of the results concerning SUMOylation regulating these mechanisms have been 
obtained from macrophages, although the same principles have been detected in 
microglia and astrocytes in the brain through the orphan receptor NURR1 (Pascual et 
al. 2005; Ghisletti et al. 2007 and 2009; Saijo et al. 2009). In addition, SUMOylation 
of LXRs was shown to modulate the IFN (interferon) γ-mediated inflammation in 
brain astrocytes with SUMO-1-specific modification of LXRβ and SUMO-2/3 
modification of LXRα using the PIAS1 and HDAC4 as E3 enzymes, respectively 
(Lee et al. 2009). Interestingly, in macrophages, SUMOylation of both LXR paralogs 
is carried out by SUMO-2/3, and they block NCoR turnover by binding to a 
conserved SUMO2/SUMO3-interaction motif in CORO2A and preventing actin-
mediated NCoR clearance (Ghisletti et al. 2007; Huang et al 2011). In macrophages, 
SUMO-1-modified PPARγ mediates transrepression of a subset of genes in a ligand-
dependent manner (Pascual et al. 2005; Jennewein et al. 2008).  
 
3.3 Stress and SUMO 
 
The finding that SUMO-2/3 is largely in free form in the cell, as opposed to SUMO-1 
that is usually covalently bound to substrates, was the first hint towards free SUMO-
2/3 being a reserve related to stress situations and mobilized when needed (Saitoh and 
Hinchey 2000). The authors tested several cellular stressors on cultured monkey 
kidney cells and noted accumulation of high molecular weight SUMO-2/3 conjugates 
upon exposure to heat, oxidative stress, ethanol and osmotic stress. In vivo, 
experimental stroke models with occlusion to transient middle cerebral artery resulted 
in massive SUMOylation at the infarct area mostly with SUMO-2/3 (Cimarosti et al. 
2008; Yang et al. 2008). Responses to hypoxia are, however, not limited to SUMO-
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2/3 only, as hypoxia also increases Sumo1 mRNA levels of in vitro and in vivo 
(Comerford et al. 2003; Shao et al. 2004). SUMO-1 has been shown to regulate the 
stability of HIF1 (hypoxia-inducible factor 1) that is a dimeric protein stabilized under 
hypoxic conditions and regulates directly expressions of genes involved in survival 
under these conditions, such as Epo (Wang et al. 1995a). The consequences of HIF1α 
SUMOylation are contradictory, with one study showing increased stability and 
activity of the protein upon SUMOylation while two other reports claim the contrary 
(Bae et al. 2004; Carbia-Nagashima et al. 2007; Berta et al. 2007). Although in 
general, hypoxia tends to increase the global SUMOylation, this does not necessarily 
apply to all proteins, as in human corneal epithelial cells it was found that hypoxia 
induces de-SUMOylation of CTCF despite increased universal SUMOylation (Wang 
et al. 2012). There is evidence from yeast that SUMOylation of multiple enzymes 
shifts the metabolism of cells to favor glycolysis under hypoxic conditions (Agbor et 
al. 2011).  
 
Not only hypoxia but also oxidative stress has been linked to SUMOylation as H2O2 
treatment resulted in increased SUMOylation (Saitoh and Hinchey 2000; Zhou et al. 
2004; Manza et al. 2004). However, with lower concentrations of H2O2, global 
SUMOylation decreases because of inactivation of the E1 and E2 enzymes through 
formation of thioesther bonds by the reactive oxidative species (ROS) (Bossis et al. 
2006). Again, SUMO modification of single proteins may have tremendous effects on 
the cell fate in oxidative stress, as demonstrated by HIPK2 (homeodomain-interacting 
protein kinase 2) that has redox sensor activity. With increasing levels of H2O2, 
HIPK2 is deSUMOylated, which causes dissociation of HDAC3 from the complex. 
The resulting hyperacetylation of HIPK2 improved cell survival and resistance to 
ROS (de la Vega et al. 2012). SUMOylation may thus have clinical implications in 
the treatment of cancer, where cancer cells have become insensitive to oxidative stress 
and create strategies to evade apoptosis (Hanahan and Weinberg 2011). 
 
3.4 SUMO and chromosomal stability 
 
Genotoxic stress such as ionizing radiation causes DNA damage that the cell tries to 
repair by activating one or many of the DNA damage response (DDR) pathways to 
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avoid passing a potentially harmful mutation forward to daughter cells and, in case 
this fails, the cell – if part of a multicellular organism – usually activates the 
programmed cell death (apoptosis) pathway. SUMOylation is involved in the 
regulation of this at multiple points. Intriguingly, one of the most important regulators 
of chromosomal stability, the tumor suppressor protein p53, is stabilized by SUMO 
(Gostissa et al. 1999; Rodriguez et al. 1999).  
 
Base excision repair. Single bases in DNA may be damaged by deamination, 
oxidation or alkylation. These non-fitting bases are removed by glycosylases leaving 
behind an abasic nucleotide removed by AP (apuric or apyrimidic) endonucleases. 
The filling of the resulting gap is catalyzed by DNA polymerases and ligases. One of 
the glycosylases modified by SUMO is TDG, which removes the sugar moiety of 
thymine or uracil when mismatched with guanine (Takahashi et al. 2005). 
SUMOylation of TDG results in dissociation of TDG from the site allowing the repair 
pathway to proceed (Hardeland et al. 2005).  
 
Double strand break (DSB) repair. DSBs are caused by genotoxic agents, γ-
irradiation or faulty replication and are usually efficiently repaired either by non-
homologous end joining or homologous recombination (HR). The cell may also create 
DSBs as part of normal meiosis in testes and ovaries when the chromosomes 
exchange genetic material. SUMOylation of several proteins accumulated in the DSB 
foci has been reported (Bergink and Jentsch 2009). The DSB brings about a cascade 
of events leading to the accumulation of repair proteins in the vicinity of damaged 
DNA. Phosphorylation by the ATM/ATR/DNA-PK pathway is an important event, 
leading to formation of phospho-H2AX, a hallmark of DNA damage, which functions 
as a docking site for the ubiquitin E3 ligase RNF8 (Rogakou et al. 1998; Mailand et 
al. 2007). The ubiquitination of several other proteins catalyzed by RNF8 allows 
complexes containing p53BP1 (p53-binding protein 1) and BRCA1 (breast cancer 1, 
early onset) to assemble. Interestingly, the presence of PIAS1 and PIAS4 is also 
required for p53BP and BRCA1 to load onto the damage site (Galanty et al. 2009). 
Furthermore, BRCA1, a ubiquitin E3 ligase itself, is modified by SUMO, and SUMO 
conjugates are assembled onto the damaged loci (Morris et al. 2009). p53BP1 and 
MDC1 (mediator of DNA-damage checkpoint 1), a scaffold protein recognizing the 
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phospho-H2AX, are also SUMO substrates (Vyas et al. 2012). It seems that DSB 
repair is a complex cascade of events requiring the correct timing of different PTMs 
and assembly of a large array of DNA repair proteins, a process far from being 
understood in full detail. 
 
A DSB may also result during S-phase, if the replication fork collapses at an 
unrepaired DNA lesion. An important protein orchestrating the events at the 
replication fork, PCNA, has several interaction partners depending on its PTMs. The 
same Lys164 may be modified by mono-ubiquitination leading to error-prone post-
replication repair (PRR) via the translesion synthesis. However, if the same Lys is 
poly-ubiquitinated, error-free PRR results. The same Lys may also be SUMOylated 
leading to inhibition of HR, which might lead to chromosomal instability at an 
unrepaired DSB (Hoege et al. 2002). The SUMOylated PCNA is recognized by the 
SIM of Srs2, the crystal structure of which has recently been resolved (Armstrong et 
al. 2012). The mechanisms have been studied mostly in yeast but many of the proteins 
involved are conserved in mammals. However, mammalian cells lack a homologue 
for Srs2 and, therefore, the mediator recognizing the SUMOylated PCNA remains to 
be identified, although the same conserved Lys164 is SUMOylated in human cells 
(Gali et al. 2012).  
 
3.5 SUMO and human diseases 
 
Cancer. As might be expected from the role of SUMOylation in DNA damage repair, 
genes of the SUMOylation pathway have also been implicated in human cancers 
(Bettermann et al. 2012). Lung adenocarcinoma, ovarian and cervical carcinoma, 
colon and prostate cancer have all been reported to have higher expression of UBC9 
compared to normal tissue from the same patients (McDoniels-Silvers et al. 2002; Mo 
et al. 2005; Moschos et al. 2010). However, both colon and prostate cancer metastatic 
lesions show lower levels of UBC9 mRNA compared to normal tissue (Moschos et al. 
2010). UBC9 has, therefore, been proposed to be a potential drug target. It is possible 
that the changes observed in SUMOylation of cancerous tissues are related to the 
tumor microenvironment characterized by changes in metabolism, hypoxia, 
inflammation and genotoxic stress, situations that are all related to SUMOylation. The 
relationship between SUMO and cancer is likely to be very complex, as many of the 
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cancers mentioned above are highly dependent on steroid hormone signaling, and 
therefore, SUMOylation may have a specific role in each cancer type.   
 
Neurodegenerative diseases. Huntington’s disease (HD) is a neurodegenerative 
disease characterized by the accumulation of a pathogenic form of huntingtin (Htt) 
exhibiting an expanded polyglutamine tract. Htt was shown to be SUMOylated and in 
the Drosophila model of HD, SUMOylation of Htt leads to exacerbation of the 
disease (Steffan et al. 2004). Other neurodegenerative diseases have been associated 
with SUMOylation as well. Both α-synuclein and DJ-1, proteins involved in 
Parkinson’s disease, are known SUMO-substrates (Dorval and Fraser 2006; Shinbo et 
al. 2006). APP (amyloid precursor protein) and Tau, two proteins contributing to the 
plaques and Tau filaments accumulating in Alzheimer’s disease, are both targets for 
SUMOylation (Li et al. 2009; Dorval and Fraser 2006). Despite several animal 
models and in vitro results, final evidence showing that SUMOylation is involved in 
human neurodegenerative diseases is not yet available. 
 
Infections. Various human intracellular pathogens have evolved to modulate or 
benefit from the SUMOylation system. The best studied are adenoviruses and herpes 
viruses that have been shown to disrupt the PML-NBs, natural antiviral structures of 
the nucleus (Van Damme and Van Ostade 2011). DNA of Herpes simplex virus-1 
moves to the nucleus upon entrance of viral particles into the host cell and localizes to 
the PML-NB where Daxx1, Sp100 and PML act as an antiviral defense. The virus 
fights this with an immediate early protein aiming at destruction of SUMOylated 
proteins of the PML-NB (Müller and Dejean 1999). Other viruses and even 
intracellular bacteria have also been shown to hijack the SUMOylation machinery 
(Wimmer et al. 2012). 
 
4. Adipose tissue 
 
PPARγ, post-translationally modified by SUMO, is the master regulator of the 
adipose tissue, an important endocrine organ affecting whole body energy 
homeostasis and insulin sensitivity by secreting adipokines. White adipose tissue 
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(WAT) stores energy whereas brown adipose tissue (BAT) burns it by generating heat 
through mitochondrial uncoupling of respiration from ATP production.  
 
4.1 White adipose tissue 
 
White adipose tissue comprises mainly unilocular adipocytes, fibroblasts, nerves, 
endothelial cells and immune cells. It is present subcutaneously and around internal 
organs, the latter of which is considered metabolically more important as its 
circulation drains directly to the liver (Smorlesi et al. 2012). All adipocytes are 
derived from mesenchymal stem cells (MSC) present in the stromal vascular fraction 
of the adipose tissue. The first transition into committed preadipocytes upon 
activation by messages from the extracellular matrix is not entirely clear, but is 
known to involve signaling via WNT pathway and the transforming growth factor 
(TGF)-β family (Cristancho and Lazar 2011). A recently found marker for committed 
preadipocytes is Zfp423 that sensitizes the cells to BMP (bone morphogenic protein), 
a member of the TGFβ family (Gupta et al. 2010). The terminal differentiation has 
been studied in more detail, although a majority of the results are derived from in 
vitro differentiation studies using a single cell line, the murine preadipocyte cell line 
3T3-L1 (Green and Meuth 1974). A large number of TFs modulate adipogenesis, but 
the main players are PPARγ and the CCAAT-enhancer-binding proteins (C/EBPs) 
(Lefterova et al. 2008; Nielsen et al. 2008). In committed adipocytes, low level of 
C/EBPβ is bound on stretches of chromatin that display marks for active enhancers 
(hotspots) while PPARγ level is very low. Upon addition of the adipogenic cocktail – 
typically consisting of a glucocorticoid, cAMP agonist and insulin – these hotspots 
recruit binding of other adipogenic TFs such as C/EBPδ, STAT5A, GR and RXR 
(Siersbæk et al. 2011). The early TFs also induce the late adipogenic factors, PPARγ 
and C/EBPα, which together induce and maintain the expression of metabolic genes. 
It has been demonstrated in vivo and in vitro that adipogenesis does not occur in the 
absence of PPARγ, and the Cebpa null mice die at 8 h postnatally exhibiting adipose 
tissue unable to store lipids (Barak et al. 1999; Rosen et al. 1999; Wang et al. 1995). 
Together they also form a positive autoregulatory loop maintaining their own 
expression (Wu et al. 1999). 
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WAT stores energy as triglycerides within its unilocular fat droplets. It also 
communicates with the rest of the body by secreting its own hormones, adipokines, 
into the blood stream (Ouchi et al. 2011). The role of leptin was demonstrated by the 
ob/ob mouse harboring a mutation in the leptin gene. Leptin functions via the central 
nervous system as an anorexigenic hormone, and consequently, the mouse model 
exhibits hyperphagia and severe obesity, which are reversed by leptin administration 
(Zhang et al. 1994). Another proinflammatory adipokine is resistin, mediating insulin 
resistance (Steppan et al. 2001). Although secreted robustly by adipocytes in mice, 
resistin may not be a true adipokine in humans, where it is secreted by macrophages, 
although it seems to have a similar function in carbohydrate metabolism and insulin 
signaling as the murine counterpart (Qatanani et al. 2009; Park et al. 2011). An 
important anti-inflammatory adipokine is adiponectin that acts via adiponectin 
receptors in muscle and liver to boost fatty acid oxidation and inhibit 
gluconeogenesis, respectively (Tomas et al. 2002; Yamauchi et al. 2002). 
 
4.2 Brown adipose tissue 
 
There is increasing evidence that adult humans possess functional BAT, previously 
thought to be present only in infants and hibernating animals (Virtanen et al. 2009; 
van Marken Lichtenbelt et al. 2009; Cypess et al. 2009). It is located in depots in the 
neck and around clavicles and activated upon cold exposure (Ouellet et al. 2012). 
Furthermore, there is a strong inverse relationship between obesity and the amount of 
BAT in humans (Saito et al. 2009; van Marken Lichtenbelt et al. 2009). The ability of 
BAT to produce heat is dependent on uncoupling protein 1 (UCP1) which allows 
energy to be consumed and released as heat instead of being stored as fat. This 
protects the body against cold and may prevent obesity by burning calories.  
 
Similar to white adipocytes, the brown adipocytes are derived from MSCs. However, 
early on in the differentiation, the two lines diverge and result in committed white 
preadipocytes and myogenic factor 5 (MYF5) positive myoblastic precursor cells, 
which have the potential to differentiate into muscle cells and brown adipocytes 
(Seale et al. 2008). The lineage specific TF promoting the differentiation to the 
direction of brown adipocytes is PRDM (PR domain containing) 16, a zinc-finger 
protein working in complex with C/EBPs (Seale et al. 2007). PRDM16 is such a 
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robust inducer of the brown adipocyte program that even fibroblasts expressing 
ectopically the protein assume the brown adipocyte phenotype (Kajimura et al. 2009). 
Other TFs required for the brown adipocyte development are again PPARγ and the 
C/EBPs along with a PGC1α (peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha), which is essential in mitochondrial biogenesis and highly 
expressed in BAT (Kajimura et al. 2010). Interestingly, SUMOylation of PGC1α has 
been found to attenuate its functions in vitro, possibly by enhancing its interaction 
with RIP140 (Rytinki and Palvimo 2009). RIP140 is a transcriptional corepressor 
antagonizing the effects of PGC1α and part of the white adipocyte signature (Powelka 
et al. 2006). 
 
A recent breakthrough in the adipocyte field is the finding that brown-like adipocytes 
may appear in WAT depots (Vegiopoulos et al. 2010; Petrovic et al. 2010). Browning 
of the WAT has been known previously, but the novelty of the studies was the 
molecular signature showing that they are a distinct population of cells resembling the 
brown adipocytes but lacking some of their characteristics such as the expression of 
PRDM16. These brown-like cells are called beige or brite, and they have evoked high 
hopes in the battle against obesity, as they literally burn fat. A crucial question still 
remains whether the beige cells arise from stem cells or through transdifferentiation 
from white adipocytes and whether this process could be modified pharmacologically. 
The transdifferentiation theory was initially thought to explain the phenomenon 
(Barbatelli et al. 2010). However, there is recent evidence that a subpopulation of 
cells in the stromal vascular fraction could be beige stem cells, and the BAT depots in 
humans would be more beige than brown, i.e., derived from the MYF5-negative 
precursors (Wu et al. 2012). The white-to-beige conversion is induced by both 
exposure to cold and physical exercise, possibly through sympathetic activity 
(Barbatelli et al. 2010; Smorlesi et al. 2012). A hormone released from the muscles 
during physical exercise was recently shown to induce the browning of WAT. This 
newly identified hormone was named irisin (Boström et al. 2012). 
 
4.3 Obesity 
 
Consumption of excessive amounts of food combined to a sedentary lifestyle has led 
to a world-wide epidemic of obesity, which is associated with type 2 diabetes, fatty 
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liver, cardiovascular diseases and osteoarthritis. Weight gain results when calorie 
intake exceeds calorie consumption. WAT can expand to a certain point by 
hyperplasia and hypertrophy, but at some point the adipocytes become saturated with 
fat, leading to inflammation (Stienstra et al. 2012). The inflamed adipocytes secrete 
inflammatory mediators, such as TNFα and IL (interleukin)-1β, attracting 
macrophages and activating the ones already residing in the tissue. This is thought to 
contribute to the whole-body insulin resistance seen in obesity (Weisberg et al. 2003; 
Xu et al. 2003). Macrophages display two opposing polarization states. Lean WAT 
typically contains M2 polarized (alternatively activated) macrophages that secrete 
anti-inflammatory signals, whereas obese WAT makes macrophages to assume an M1 
(classically activated) state promoting inflammation (Prieur et al. 2011; Zeyda et al. 
2007). An altered inflammatory status of the WAT in obesity is also evident, in that 
lean but not obese mice had a specific subpopulation of regulatory T-cells in their 
abdominal WAT and, interestingly, PPARγ was required for them to maintain insulin 
sensitivity of the body (Feuerer et al. 2009; Cipolletta et al. 2012). This may have 
implications in the treatment of diabetes, where many of the PPARγ agonists have 
failed due to side-effects including weight gain (Nesto et al. 2003; Cariou et al. 2012). 
 
Besides the pathological low-grade inflammation, obesity involves dysregulation of 
the adipokines. Leptin levels are elevated in obese individuals but due to leptin 
resistance, the hormone fails to exert its hypothalamic anorexigenic response 
(Friedman and Halaas 1998; Maffei et al. 1995). Accordingly, exogenously 
administered leptin is not a promising drug in obesity, but may turn out to be useful in 
treatment of diabetes (Coppari and Bjørbæk 2012). The role of resistin in the 
pathophysiology of obesity is somewhat unclear, but adiponectin levels show a clear 
decrease in obese people (Heilbronn et al. 2004; Ryo et al. 2004).  
 
5. Testis 
 
Testis is the site of male germ cell maturation and the main source of androgens. It 
has developed its own mechanisms to protect the delicate process of sperm production 
by tightly regulating the molecular environment by the testis-blood barrier. With a 
high cell division activity – approximately 100 to 200 million sperm cells are 
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produced daily – it is important to regulate the cell cycle and keep the chromosomes 
stable, functions where the SUMOylation system comes to play (Vigodner 2011). The 
functions of testis are ultimately orchestrated by hypothalamic hormones, the 
luteinizing hormone stimulating androgen production by the Leydig cells and the 
follicle-stimulating hormone acting on the Sertoli cells, the somatic cells that nurture 
the developing sperm. Knowledge about the mechanisms of spermatogenesis is 
needed in order to solve the mystery of declining sperm quality in the western 
countries (Andersson et al. 2008).  
 
5.1 Development 
 
Primordial germ cells migrate from the yolk sac to the posterior body wall where they 
induce the genital ridges early in the embryogenesis (fifth week in humans; E10.5 dpc 
in mice). The surrounding epithelium and the mesonephros, a temporary embryonic 
structure, start invading the genital ridges and form the primitive sex cords with 
cortical and medullary regions, similar in both sexes at this point. Testis development 
follows when the sex-determining region of the Y chromosome (SRY) is present and 
when it is absent, an ovary is formed (Sinclair et al. 1990; Gubbay et al. 1990; Vainio 
et al. 1999). The SRY protein makes the medulla of the sex cords to differentiate into 
Sertoli cells that start to produce Anti-Müllerian hormone acting in the surrounding 
tissues to degenerate the Müllerian ducts that in females form the oviducts. In males, 
the medullary sex cords (the future seminiferous tubules) connects to the mesonephric 
tubule that later forms the epididymis (Tilmann and Capel 1999). Simultaneously, at 
week 9-10 (E13.0 dpc in mice), the SRY causes mesenchymal cells of the gonadal 
ridge to differentiate into Leydig cells that start expressing genes needed for androgen 
production (Baker et al. 1999). By weeks 13-15, fetal testosterone levels have reached 
a high concentration, which is required for seminal vesicles, prostate and 
bulbourethral glands to develop and the external genitalia to assume the male 
phenotype. Before birth, the testes descend to the scrotum, a process guided by a 
ligamentous structure called gubernaculum and highly dependent on androgen action 
(Bay et al. 2011). Should the descent fail, the testes have to be surgically aided to 
their correct position to prevent testicular cancers and to preserve fertility, as 
spermatogenesis, starting at puberty, cannot take place in too high temperature. In 
mice, the germ cells undergo mitotic arrest at E13.5–E15.5, and they start dividing 
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again 3–4 days after birth giving rise to the first mature sperm around day 42, when 
the mice reach puberty (Nel-Themaat et al. 2010). Spermatogenesis in humans is also 
delayed until puberty, when the testes start producing large amounts of androgens in 
response to the pulsatile activity of the hypothalamus-pituitary-axis (Nielsen et al. 
1986).  
 
5.2 Spermatogenesis 
 
Spermatogenesis is a complex, multistep process where cohorts of diploid cells 
undergo meiosis resulting in mature sperm cells. This takes place in seminiferous 
tubules and requires male hormones (Fig. 5A). In mice, the seminiferous tubules are 
histologically organized into stages I–XII, where germ cells within each layer of the 
seminiferous epithelium change in synchrony with the other layers over time (Fig. 
5B). The spermatogonia are in the outer part of the tubule and as the differentiation 
proceeds, the cells move towards the center of the lumen. Spermatogenesis is divided 
into three phases: mitotic phase, meiotic phase and spermiogenesis (Jan et al. 2012). 
 
Mitotic phase. The germ cells at the outer layer of the seminiferous tubules divide 
mitotically. These spermatogonia divide mitotically giving rise either to new stem 
cells or differentiating spermatogonia (Yoshida 2012). Cohorts of spermatogonia are 
recruited simultaneously, and they maintain connections through cellular openings. 
The differentiating cells divide mitotically several times further and become type B 
spermatogonia. When they enter the prophase of meiosis, they are called primary 
spermatocytes. 
 
Meiotic phase. The pre-leptotene spermatocytes duplicate their DNA. In the following 
leptotene phase, chromatin condenses leading to zygotene spermatocytes, where the 
homologous chromosomes start pairing. The exchange of genetic material through 
homologous recombination takes place in the pachytene spermatocytes. The 
homologous autosomal chromosomes form crossovers while the sex chromosomes are 
protected from promiscuous recombination in the XY body (Hoyer-Fender 2003). In 
diplotene spermatocytes, the synaptonemal complex holding the homologous 
chromosomes together is decomposed, and the cells are ready for the first meiotic 
division (Page and Hawley 2004). Homologous recombination involves the creation 
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of DNA DSBs and, therefore, many of the proteins involved in DNA repair are 
abundant in testis. It has been shown that loss of Rnf4 that encodes the ubiquitin 
ligase targeting SUMOylated proteins and essential in DSB repair not only renders 
mice more sensitive to ionizing radiation but also leads to defects in spermatogenesis 
(Vyas et al. 2012). The secondary spermatocytes resulting from the first meiotic 
division immediately enter the second division and become spermatids that contain a 
haploid genome with either the X or Y chromosome.  
 
Spermiogenesis. During the last phase of spermatogenesis, the spermatids undergo 
nuclear condensation and formation of the tail and an acrosome that contains the 
enzymes needed to penetrate the oocyte. The chromosomes obtain a supercondensed 
state to protect DNA, leading to silencing of the transcription altogether. The 
protection of DNA at this stage involves a number of epigenetic mechanisms such as 
non-coding RNAs and post-translational modification of proteins in contact with 
DNA and direct DNA modifications (Carrell 2012; Hamatani 2012). The histones are 
first replaced by transition proteins, which soon are replaced by protamines (Meistrich 
et al. 2003; Yelick et al. 1987). The process where the haploid sperm cells are 
released into the lumen leaving behind part of its cytoplasm is called spermiation. 
Finally, the spermatozoa are moved with the help of myotubular cells towards the 
epididymis for maturation to gain the ability to move and fertilize an egg. 
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Figure 5. A. Gross anatomy of testis with a zoom into the seminiferous epithelium 
(Adapted from Cooke and Saunders 2002) B. Stages of the murine spermatogenic 
cycle as depicted in Russell et al. 1990. 
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AIMS OF THE STUDY 
 
 
SUMOylation is an important post-translational modification affecting a plethora of 
cellular functions ranging from chromosomal stability to regulation of protein–protein 
interactions. SUMO paralogs share significant functional and structural similarities 
and are partially able to compensate for each other. This study aimed at understanding 
the in vivo functions of SUMOylation by creating two knock-out mouse lines and 
analyzing them under different conditions. The following specific aims were 
addressed: 
 
 
1. Physiological role of the Pias2 gene, a SUMO E3 ligase, by gene 
disruption in mice with emphasis on testis function 
2. SUMOylation pathway in spermatogenesis in normal and Sumo1 null mice 
3. General phenotype characterization of the Sumo1 null mice 
4. SUMO-1 in inflammation in vivo 
5. Importance of SUMO-1 in energy metabolism  
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MATERIALS AND METHODS 
 
Generation of knock-out mice 
 
Pias2 knock-out mice were generated using the gene-trap method (Wiles et al. 2000; 
Hansen et al. 2003).  Embryonic stem cells (ESC) were electroporated with PT1βgeo 
gene-trap vector, which contains an En2 splice acceptor site upstream of a β-
galactosidase/neomycin-resistance fusion gene (βgeo). Random gene-trap vector 
integration occurred in the second intron of the Pias2 gene, as determined by 
sequencing of the fusion transcript. The insertion of the gene trap in the second intron 
results in a transcript devoid of exons 3–13 and 3–14 of PIASxα (ARIP3) and 
PIASxβ (Miz1), respectively (Fig. 6A). PIASxα and PIASxβ are transcripts resulting 
from alternative splicing at the 3’ end of the Pias2 gene. The mice were backcrossed 
with C57Bl/6 mice for several generations. Sumo1 knock-out mice were created using 
direct gene-targeting. A targeting vector was constructed comprising sequences 
flanking exons 3, 4 and 5 and selection markers resulting in deletion of exons 3–5 of 
the Sumo1 gene from the genome (Fig. 6B). ESCs were electroporated with the 
targeting vector and colonies surviving the G418 (presence of the positive selection 
marker Neo) and ganciclovir (absence of the thymidine kinase gene outside of the 
homologous sequence) exposure were screened by PCR and Southern blot analysis, 
after which the positive cells were used for morula aggregations. The Sumo1 knock-
out mice were analyzed as littermates in a mixed 129Sv/ICR background. 
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Figure 6. Constructs for generation of the mutant mice A. Pias2 null mutant B. 
Sumo1 null mutant. En-2 = engrailed 2, Neo = neomycin resistance gene, pA = SV40 
polyadenylation signal, tk = the thymidine kinase gene, PGKNeo = phosphoglycerate 
kinase I (PGK) promoter, neomycin resistance gene (Neo) 
 
 
Treatments of mice 
 
All mice were handled in accordance with the institutional animal care policy of the 
University of Helsinki, and the University of Helsinki Review Board for Animal 
Experiments approved all animal protocols. 
 
High-fat diet 
In high-fat diet (HFD) studies, six-week-old wild-type (WT) or Sumo1 null (KO) 
mice were fed chow (TD06416) or high-fat diet (TD06414) from Harlan Laboratories 
(Indianapolis, IN) ad libitum for 17 weeks. Food consumption was based on weekly 
food weight measurements for 12 weeks. Abdominal fat and lean tissue volumes were 
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determined by imaging the abdominal area of the mice with MRI using a 4.7 T 
scanner (PharmaScan, Bruker BioSpin, Germany).  
 
Drug administration 
Rosiglitazone (Cayman Chemical, Ann Arbor, MI) was given by oral gavage for 4 or 
13 days at a dose of 10 mg/kg/day. LPS (10 mg/kg, Sigma-Aldrich, St. Louis, MO) 
was given intraperitoneally for 6 h before dissection. 
 
Glucose and insulin tolerance tests 
For the intraperitoneal glucose tolerance test, mice were fasted overnight (16 h). Each 
mouse was given glucose 2 g/kg i.p., and blood glucose concentration was measured 
from tail vein samples at 0, 15, 30, 60 and 120 min using the OneTouch UltraEasy 
meter (Life Scan, Milpitas, CA). For the insulin tolerance test, mice were fasted for 4 
h. The mice received human insulin (Humulin Regular, Lilly, Indianapolis, IN) 1 
U/kg i.p., and blood glucose concentration was determined at 0, 30, 60 and 90 min.  
 
Other measurements 
Rectal temperature was measured using the BAT-12 thermometer (Physitemp 
Instruments, Clifton NJ). Fecal fat was extracted from dried feces by 
chloroform:methanol (2:1, by vol.), and the extract evaporated to dryness and 
weighed. After sacrifice of the mice, their gonadal fat pads were dissected and 
weighed. A small sample was cut, weighed and dispersed with 500 U/ml collagenase 
in 2% BSA and centrifuged at 1,000 x g for 5 min. DNA content of the adipocytes 
was measured using the Fluorescent DNA Quantification Kit (Bio-Rad, Hercules, 
CA). 
 
Cell culture 
 
MEFs were derived from 13.5-day-old WT and Sumo1 null embryos. After removal 
of the head and gastrointestinal tract, the embryos were washed with phosphate-
buffered saline and minced, and the tissues were placed into a 15-ml conical tube. A 
total of 5 ml of trypsin solution (0.025% trypsin, 1 mM EDTA) was added to the 
minced tissues, and cell suspensions were incubated at 37°C for 1 h with stirring. 
After centrifugation (1,000 rpm, 5 min), the cell pellets were washed twice with and 
Materials and methods 
 53 
resuspended in 10 ml of Dulbecco modified Eagle medium (DMEM) plus 10% fetal 
calf serum. Single-cell suspensions were plated onto 6-cm dishes that were incubated 
at 37°C for 2 to 3 days until confluence. MEFs were immortalized by culturing the 
cells until passage 18. 
 
Quantitative RT-PCR 
 
Total RNA was isolated from cells or tissues using the RNEasy Mini Kit (Qiagen 
GmbH, Hilden, Germany) or TRIzol reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturers’ instructions. cDNA was synthesized from 1 μg of total RNA using 
random hexamer primers and Superscript III First-Strand Synthesis System 
(Invitrogen) according to the manufacturer’s instructions. qRT-PCR was performed 
with LightCycler® 480 Real-Time PCR System (Roche, Diagnostics, Indianapolis, 
IN) in 20-μl reactions containing SYBR Green I Master (Roche) and 1 μM forward 
and reverse primers. PCR reaction included a 5-min denaturation step at 95°C 
followed by 40 cycles of 10-s denaturation at 95°C, 5-s annealing at 57–60°C, 20-s 
extension at 72°C and 5-s SYBR Green signal measurement. The results were 
analyzed with LightCycler analysis software (Roche) and were normalized to 18S 
rRNA or Gapdh mRNA levels.  
 
RNA blotting 
 
Total RNA (10 μg) collected from murine tissues were resolved on 1.2% 
formaldehyde agarose gels and transferred onto nylon membranes (Hybond-XL; GE 
Healthcare, Little Chalfont, United Kingdom). The blot was hybridized with a 32P-
labeled antisense RNA probe (1.7 x 106 cpm/ml) for 2 h at 68°C in ULTRAhyb buffer 
(Ambion, Austin, TX). After washes with 2 x SSC (1 x SSC is 0.15 M NaCl, 0.015 M 
sodium citrate) and 0.1% sodium dodecyl sulfate (SDS) (twice for 5 min at 68°C) and 
with 0.1 x SSC and 0.1% SDS (twice for 15 min at 68°C), the membrane was exposed 
to Fuji X-ray film at -70°C for 24 to 72 h. 
 
Histological analyses 
 
WAT and testis samples were fixed immediately after dissection in 4% 
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paraformaldehyde at 4°C overnight, dehydrated and embedded in paraffin. Five-µm 
sections were mounted onto Superfrost Plus slides (Menzel GmbH, Braunschweig, 
Germany), dewaxed with xylene, rehydrated and counterstained using Mayer’s 
hemalum solution (Merck, Darmstadt, Germany). The slides were dehydrated and 
mounted using Permount (Fisher Chemicals, Fair Lawn, NJ). 
 
In situ hybridization 
 
Sections (5 μm) of testis tissues at the different developmental stages were used for in 
situ hybridization. Sections were deparaffinized in xylene and rehydrated in 
descending concentrations of ethanol. Hybridization with antisense or sense probes 
was carried out in prehybridization solution containing 10% dextran sulfate and 0.5 x 
105 to 1 x 105 cpm of cRNA probe/ml at 50°C for 4 h. After hybridization, tissue 
sections were treated for 30 min at 37°C with 10 μg of RNase A/ml, washed twice for 
15 min at 50°C with 1 x SSC, and dehydrated in a graded series of ethanol containing 
0.3 M ammonium acetate (pH 5.2). The slides were coated with Kodak NTB-3 
emulsion (Eastman Kodak Company, Rochester, NY) and stored at 4°C in light-tight 
boxes for 1 to 3 weeks. After development, the slides were counterstained with 
hematoxylin. 
 
Immunohistochemistry 
 
Testes from 10-day-old and adult mice were fixed overnight in 4% paraformaldehyde 
at 4°C, dehydrated, and embedded in paraffin. Sections (5 μm thick) were mounted 
onto SuperFrost Plus slides (Menzel), dewaxed, and rehydrated. Endogenous 
peroxidase activity was blocked by incubation in 3% hydrogen peroxide in methanol. 
Slides were boiled for 15 min in 10 mM sodium citrate (pH 6.0) for antigen retrieval, 
washed in Tris-buffered saline (TBS), and blocked in TBS containing 1% bovine 
serum albumin (Sigma-Aldrich) and 3% normal house or goat serum (Vector 
Laboratories, Burlingame, CA). Slides were incubated with primary antibody (anti-
SUMO-1 [Santa Cruz Biotechnology, Santa Cruz, CA]; anti-SUMO2/3 [ab3742; 
Abcam, Cambridge, United Kingdom]) overnight at 4°C. After three washes in TBS, 
biotinylated anti-mouse immunoglobulin G was applied on sections and incubated for 
1 h at room temperature. Visualization of the reaction was carried out by using the 
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Vectastain Elite ABC and peroxidase DAB substrate kits (Vector Laboratories) 
according to the manufacturer’s instructions. Slides were dehydrated in ascending 
ethanol series and mounted in Permount mounting medium (Fisher Chemicals). 
 
Protein isolation and immunoblotting 
 
Proteins were isolated from cells or tissues using a buffer containing 50 mM Tris-HCl 
(pH 7.8), 300 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 10 mM N-
ethylmaleimide (Sigma-Aldrich), and 1 x complete protease inhibitor set (Roche). 
Lysates were centrifuged, and soluble protein concentration was quantified with the 
BioRad protein assay. Protein samples (50 μg) were resolved by 10% SDS-PAGE and 
transferred onto ECL membrane (GE Healthcare). Immunoblotting was performed 
using rabbit polyclonal PPARγ antibody (81B8, Cell Signaling Technology, Danvers, 
MA), mouse monoclonal SUMO-1 antibody (SC-5308, Santa Cruz Biotechnology), 
β-actin antibody (sc-47778, Santa Cruz Biotechnology) or α-tubulin antibody (sc-
5286, Santa Cruz Biotechnology). Horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit IgG was used as a secondary antibody. ECL reagent (GE 
Healthcare) was used for visualization.  
 
Immunoprecipitation 
 
For immunoprecipitation experiments, MEFs and tissues were homogenized in a 
buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 
0.5% Nonidet P-40, 0.1% sodium deoxycholate, 1% protein inhibitor cocktail and 20 
mM N-ethylmaleimide. Homogenates were clarified by centrifugation at 4°C for 10 
min at 5,000 rpm and precleared by incubation with 50 μl of GammaBind Sepharose 
(Amersham Biosciences) for 30 min at 4°C. After centrifugation, the precleared 
supernatants were incubated with anti-SUMO-1 monoclonal antibody (Santa Cruz 
Biotechnology), or anti-SUMO-2 MAb (Abnova) overnight at 4°C. After the addition 
of 50 μl of GammaBind Sepharose, the samples were incubated at 4°C for 1 h. The 
resin was washed four times, and the pellets were resuspended in 2 x SDS sample 
buffer. Immunoprecipitated proteins were resolved by SDS–12% polyacrylamide gel 
electrophoresis (PAGE), and immunoblotting was carried out by using polyclonal 
anti-RanGAP1 antibody (a gift from Frauke Melchior, Max-Planck Institute for 
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Biochemistry, Munich, Germany). 
 
Chromatin immunoprecipitation 
 
3T3-L1 cells (106 cells) were seeded onto 10-cm dishes and differentiated into 
adipocytes for 7 days (see below). The cells or livers of LPS-treated WT and Sumo1 
KO mice were cross-linked in 1% formaldehyde, washed with phosphate-buffered 
saline, collected by scraping, pelleted by centrifugation and lysed in buffer containing 
10 mM EDTA, 50 mM Tris-HCl and 1% SDS. Sonicated chromatin samples (200–
500 bp in size) were precleared with normal rabbit serum and GammaBind G 
Sepharose (GE Healthcare) and immunoprecipitated with PPARγ (Santa Cruz 
Biotechnology), C/EBPα (Santa Cruz Biotechnology), C/EBPβ (Santa Cruz 
Biotechnology), GPS2 (Santa Cruz Biotechnology), LRH-1 (a gift from Iannis 
Talianidis, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece)  
or NCoR (17-10260, Millipore, Billerica, MA) antibodies. Antibody-bound 
complexes were adsorbed to GammaBind G Sepharose that was sequentially washed 
with TSE I, TSE II, TSE III, and TE buffers (Kang et al. 2004). DNA was eluted from 
the matrix with 1% SDS in 0.1 M NaHCO3, cross-linking was reverted at 65°C 
overnight, and DNA isolated using QIAquick PCR purification system (Qiagen). 
Input samples were treated the same way except that no immunoprecipitation was 
performed. qRT-PCR was performed with LightCycler 480 System in 20-μl reactions 
containing SYBR Green I Master and 1 μM forward and reverse primers for the aP2 
promoter. Input values were used for normalization. 
 
Adipocyte differentiation 
 
Primary MEFs and MSCs were differentiated into adipocytes for 12 days and 3T3-L1 
cells for 7 days. Adipogenesis was induced using a mixture comprising 1 μM 
dexamethasone (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-
Aldrich), 10 μg/ml insulin (Sigma-Aldrich) and 1 μM rosiglitazone (Cayman 
Chemical) in DMEM supplemented with 10% FBS and antibiotics. After 48 h, the 
medium was changed into DMEM containing 10 μg/ml insulin and 1 μM 
rosiglitazone; this medium was replenished every two days.  
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Transfections 
 
Immortalized MEFs were transfected with FuGene (Roche) according to the 
manufacturer’s instructions. WT and KO MEFs (250,000 cells in both cases) were 
seeded onto six-well dishes and transfected next day with 2.7 μg of the PPRE-Luc 
reporter construct together with 0.15 μg of PPARγ and 0.45 μg of β-galactosidase 
expression plasmids. Luciferase and β-galactosidase activities were measured from 
cell pellets after 48 h using the Reporter Lysis Buffer (Promega, Madison WI) and β-
galactosidase assays, respectively. The measurements were conducted with a 
Luminoskan RT reader (Labsystems, Helsinki, Finland). 
 
Statistical analyses 
 
Statistical analyses were calculated with Student’s t-test from at least three 
independent experiments or biological replicate samples. The weight gain was 
analyzed by measuring the area under curve for each individual and comparing the 
different groups with Student’s t-test. 
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RESULTS AND DISCUSSION 
 
1. Disruption of Pias2 results in smaller testis weight while maintaining fertility 
through functional redundancy of the Pias genes (I) 
 
Pias2 null mice were generated with the gene trap method as part of a large-scale 
gene trap library experiment (Hansen et al. 2003). Disruption of the Pias2 gene 
resulted in viable and fertile mice born in normal Mendelian ratios. Their body weight 
did not differ from that of their littermates. However, the mice exhibited reduced 
testis weight by 23% and decreased sperm quantity, although the quality of the sperm 
was considered normal (Fig. 7A). The number of apoptotic cells, as measured by 
TUNEL staining, was increased by 74% at all stages of spermatogenesis. This is 
interesting, since Piasxa mRNA, a splice variant of the Pias2 gene, is very abundantly 
and almost exclusively expressed in Sertoli cells and developing spermatogonia and 
spermatocytes (Moilanen et al. 1999; Yan et al. 2003). The mice had normal 
circulating levels of FSH and LH, hormones that stimulate Sertoli cells and Leydig 
cells, respectively, and the intratesticular testosterone concentrations were normal, not 
explaining the observed phenotype. In search of compensatory changes in gene 
expression of other members of the gene family, Pias1, Pias3 and Piasy mRNA levels 
were measured by quantitative real-time PCR (qRT-PCR): Pias1 and Pias3 mRNA 
levels did not change, whereas Piasy mRNA level was reduced by 30% (Fig. 7B). AR 
was the first NR shown to be SUMOylated and SUMOylation was found to decrease 
its transcriptional activation (Poukka et. al 2000). Therefore, accumulation of Pem 
mRNA encoded by the Sertoli cell-specific, highly AR-dependent gene, Pem 
(Lindsey and Wilkinson 1996), was studied and found to be elevated, possibly 
resulting from decreased inhibition of AR function by SUMO (Fig. 7B).  
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Figure 7. Testicular expression of genes related to SUMOylation. A. Testis weight of 
adult WT and Pias2 KO mice B. Pias and Pem mRNA levels in WT and Pias2 KO 
testis C. mRNA levels encoded by the SUMOylation pathway genes in WT postnatal 
testis.  
 
 
2. Genes of the SUMOylation pathway are expressed in different parts of the 
developing and adult testis (II) 
 
On the basis of the studies in the Pias2 null mice, SUMOylation was suspected to 
have an important role in testicular function. Since SUMOylation has been shown to 
regulate chromosomal stability in cell division (Takahashi et al. 2006; Dawlaty et al. 
2008), the expression of different genes belonging to the SUMOylation pathway in a 
tissue with abundant cell division activity and high demand for accuracy in 
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chromosomal segregation, the testis, was found interesting. To this end, the role of 
SUMOylation in adult and developing murine testis was studied by in situ 
hybridization, RNA blotting, qRT-PCR and immunohistochemistry. During 
development, expression of Sumo1, Sae1 (AOS1), Sae2 (UBA2), and Ubc9 increased 
with age starting from very low in newborn testes. By contrast, Sumo2/3 levels were 
high in the newborn testes and diminished with age, with the levels dropping around 
day 10 postnatally (Fig. 7C). This likely reflects a dilution effect, as the number of 
germ cells begins to increase at that time, and the first pachytene spermatocytes 
appear around that time. In situ hybridization analyses of the adult testis revealed that 
Sumo1 mRNA was present in all germ cells except elongating spermatids, whereas 
the presence of Sumo2/3 mRNA was restricted to pachytene spermatocytes. It is 
important to note that the probe used could not distinguish between Sumo2 and Sumo3 
mRNAs. Sae1, Sae2 and Ubc9 were expressed to a moderate level in the germ cells, 
and all of the genes that were studied (Sumo1-3, Sae1-2 and Ubc9) were expressed in 
the Sertoli cells or Leydig cells at low levels. At the protein level, SUMO-1 and 
SUMO-2/3 antigens appeared to be concentrated in the pachytene spermatocytes in a 
structure called XY body (also known as the sex vesicle), a subnuclear compartment 
involved in sex chromosome silencing (Hoyer-Fender 2003) in both developing (day 
10) and adult testis (Fig. 8A, left panel and II). The results showed that the different 
genes in the SUMOylation pathway have distinct expression patterns and they are 
involved in sperm production. 
 
Studies on human testis by another group reported a decrease in SUMO levels in 
infertile men and showed the presence of SUMO-1 in the XY body in human 
spermatocytes (Vigodner et al. 2006). Also studies from human testicular biopsies 
confirmed the presence of SUMO-1–3 in the germ cells and showed a role for SUMO 
in the chromosome maintenance through modification of the synaptonemal complex 
that holds the homologous chromosomes together in meiosis I (Brown et al. 2008). 
The results from this study complement these previous studies by showing expression 
of the genes of the SUMO pathway primarily in the spermatocytes undergoing 
meiosis I. The testes of Pias2 null mice with an increased number of apoptotic cells 
may be due to chromosomal disturbances resulting from disturbed functions of the 
SUMOylation machinery, possibly combined to SUMO-independent functions of 
PIAS2. 
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3. Sumo1 KO mice are viable and fertile (II) 
 
Sumo1 null mice were generated to study the in vivo role of SUMOylation. The 
overall phenotype of the mice was apparently normal, and the mice were sent to the 
German Mouse Clinic, a facility to screen the phenotypes of mutant mouse lines. The 
gross anatomy did not reveal any differences between the phenotypes, and tests 
carried out at the German Mouse Clinic showed no difference in different organ 
systems and their functions. Sumo1 null mice were born according to the expected 
Mendelian ratios, and they were viable and fertile.  
 
There is a previous report in the literature claiming that Sumo1 haploinsufficiency 
leads to cleft lip and palate (CLP) (Alkuraya et al. 2006). Therefore, the fusion of the 
palate was carefully studied, but no CLP in the Sumo1 knock-out mice was detected 
throughout embryonic development. The secondary palate was not totally closed at 
E15, but there was no clear morphological difference among Sumo1-/-, Sumo1+/-, and 
Sumo1+/+ embryos. At E18.5, the secondary palate was properly fused in 43 of 44 
embryos examined; the only cleft palate was detected in a WT embryo. Serial coronal 
sections of homozygous and heterozygous Sumo-1 embryos at E18.5 confirmed that 
the closure of the palate was complete. This discrepancy between the previous work 
(Alkuraya et al. 2006) and our study (article II) may be explained by the different 
background of the mice, but this explanation seems unlikely, since another group 
reported in agreement with our findings that Sumo1 knock-out mice do not develop 
CLP and the mice are viable (Evdokimov et al. 2008). They even revived mice from 
the same gene-trap cell line used by Alkuraya et al., but failed to reproduce the results 
and detected normal amounts of SUMO-1 protein in the mice due to genomic 
rearrangements. There are reports on Sumo1 polymorphisms or deletions causing CLP 
in humans (Alkuraya et al. 2006; Song et al. 2008; Shi et al. 2009), but experiments in 
mice have failed to show any evidence for the Sumo1 deletion directly causing CLP. 
However, this does not exclude Sumo1 from being a contributing gene in a 
multifactorial disease. 
 
Since the SUMO-1 protein was shown to localize to the XY body, the testes of the 
Sumo1 null mice were studied in more detail. Immunohistochemistry showed no 
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signal with SUMO-1 antibody in the testes, confirming the lack of SUMO-1 protein 
in these mice. Interestingly, also SUMO-2/3 localized to the sex vesicle both in WT 
and Sumo1 null testes, indicating a compensatory mechanism for the loss of Sumo1 by 
Sumo2 and Sumo3 (Fig. 8A). However, Sumo2 or Sumo3 mRNA levels, as studied by 
qRT-PCR from testicular mRNA, were not changed, suggesting that Sumo2 and 
Sumo3 are expressed abundantly in WT mice and no further compensatory 
mechanisms are needed. Immunoblotting of testicular lysates with anti-SUMO-1 
antibody revealed one major SUMOylated band with a molecular mass of 90 kDa in 
WT but not in Sumo1 null lysates assumed to be the SUMOylated RanGAP1 (Fig. 
8B). In addition, a band with the molecular size of free SUMO-1 was visible, 
especially after a longer exposure time in both testis and MEF lysates of WT but not 
of Sumo1 null mice. 
 
MEFs generated from Sumo1 null embryos proliferated to a similar degree to WT 
MEFs. Immunoblotting of lysates from MEFs with anti-SUMO-1 antibody showed a 
similar pattern with testis, having one major band at 90 kDa. Immunoblotting of MEF 
and testis lysates with anti-SUMO-2 antibody revealed not only the presence of a 
band corresponding to the molecular size of free SUMO-2 but also a more intensively 
stained 90-kDa band in Sumo1-null cells than in WT cells (Fig. 8C and II). RanGAP1 
is the most abundant cellular protein modified by SUMO-1 conjugation (Müller at al. 
2001; Matunis et al. 1996). To confirm that the 90-kDa band seen in testis and MEF 
lysate blots corresponds to the SUMOylated form of RanGAP1, anti-RanGAP1 
antibody was used on the same blot and further, proteins from testis and MEFs were 
immunoprecipitated with SUMO-1 and SUMO-2/3 antibodies. The SUMOylated 
RanGAP1 band was present in WT but not in Sumo1 null MEFs after 
immunoprecipitation with anti-SUMO-1 antibody. In line with the immunoblotting 
experiments, the samples immunoprecipitated with SUMO-2/3 antibody showed a 
stronger band in Sumo1 null MEFs, suggesting that in WT cells, a only a small 
fraction of SUMOylation of RanGAP1 is represented by SUMO-2/3 conjugation. A 
similar conclusion was also reached in quantitative proteomics analyses of HeLa cells 
expressing His6-tagged SUMO-1 and SUMO-2 (Vertegaal et al. 2006). Later, it was 
suggested that RanGAP1 is equally modified by SUMO-1 and SUMO-2 but the 
SUMO-1:RanGAP1 would be more stably protected against deconjugation (Zhu et al. 
2009). In view of this, there could be some compensation by the deconjugation 
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enzyme machinery to allow RanGAP1 – and possibly other proteins – to be more 
abundantly SUMOylated by SUMO-2 in the absence of SUMO-1. 
 
 
 
 
Figure 8. Compensation of SUMO-1 by SUMO-2/3. A. Testes of WT and Sumo1 null 
mice were stained with SUMO-1 and SUMO-2/3 antibodies. B and C. 
Immunoblotting of WT and Sumo1 KO MEF lysates with SUMO-1 (B) and SUMO-
2/3 antibodies (C). 
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4. Sumo1 KO mice have an exaggerated acute phase response upon LPS 
stimulation (unpublished results and III) 
 
Previous experiments have indicated that SUMOylation plays a role in inflammatory 
responses by decreasing the expression of several inflammatory genes. Reports from 
in vitro experiments suggest that PPARγ prevents the clearance of corepressors from 
the promoters of inflammatory genes when SUMOylated by SUMO-1 (Pascual et al. 
2005; Ghisletti et al. 2007). To test this hypothesis in vivo, the mice were challenged 
with 10 mg/kg LPS i.p. for 6 h to induce a mild general inflammatory response. The 
results showed that Sumo1 null mice have elevated levels of TNFα in their serum 
after the LPS exposure compared to WT mice (Fig. 9A). Likewise, Tnfα mRNA 
levels measured from spleens of Sumo1 null mice were elevated in comparison to 
those of WT spleens (Fig. 9B). Ghisletti et al. (2007) further showed in macrophages 
that a subset of genes were specific to PPARγ-SUMO-1 (including Tnfa), whereas 
some genes belonged to the LXR-SUMO-2 pathway (Il1b) and some genes were 
affected by both pathways (Nos2). Experiments carried out in Sumo1 KO mice 
confirmed these results by showing elevated Tnfa mRNA levels in the spleen but 
normal levels of Il1b and Nos2 mRNAs upon LPS challenge (Fig. 9C-D). The 
expression of Nos2 showed a trend, but not statistical significance of upregulation in 
Sumo1 null mice. This was the first evidence that some SUMO-1 functions cannot be 
compensated for by other SUMO paralogs. 
 
LRH-1 attenuates the hepatic acute phase response (APR) together with the well-
established metabolic regulator LXR (Venteclef et al. 2006). Since the transrepression 
capacity of LXR had been shown to involve conjugation by SUMO-2/3, and the 
transrepression by PPARγ was SUMO-1 specific in macrophages (Ghisletti et al. 
2007), we were interested in the generality of SUMOylation in the regulation of NRs 
in transrepression. To investigate the roles of LXRs, LRH-1 and SUMO in hepatic 
APR in vivo, Sumo1 null mice were treated with 10 mg/kg LPS i.p., and expression 
levels of hepatic acute phase genes were analyzed by qPCR. The inflammatory 
response was significantly more pronounced in Sumo1 KO mice than in WT mice, as 
shown by increased haptoglobin, SAA and CRP mRNA levels in liver. However, the 
LPS-mediated expression of Pai1, which is not repressed by LRH-1 or LXR, was 
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indistinguishable between Sumo1 KO and WT mice. Because the absence of 
SUMOylated NRs on the inflammatory gene promoters in Sumo1 KO mice could 
explain the exacerbated inflammatory response, recruitment of NCoR, GPS2, SUMO-
1, SUMO-2/3, LRH-1, LXRs, and PPARα onto the haptoglobin promoter was 
examined. In WT mice, LRH-1 and SUMO-1 were recruited onto the haptoglobin 
promoter five-fold and four-fold compared to IgG, respectively, suggesting that 
SUMO-1-conjugated LRH-1 interacts with the NCoR complex already in the absence 
of inflammatory stimuli. LPS treatment induced partial dissociation of NCoR and 
GPS2, but not of SUMO-1 and LRH-1 (Fig. 9E, left panel). In contrast, LRH-1 was 
not recruited onto the haptoglobin promoter in Sumo1 KO mice, demonstrating the 
importance of SUMO-1 conjugation for the recruitment of LRH-1 in vivo, and LPS 
challenge induced a more complete clearance of the NCoR complex from the 
promoter in Sumo1 KO mice in comparison with WT mice (Fig. 9F, right panel). 
Expression levels of endogenous LRH-1 target genes (Shp and Cyp7a1 mRNAs), as 
well as LRH-1 recruitment to their promoters, were also increased in Sumo1 null 
mice, indicating that SUMO-1 modification influences LRH-1 repression of direct 
target genes as well. Collectively, these data indicate that SUMOylated LRH-1 
interacts with the NCoR/GPS2 complex, and prevents its dismissal from the 
haptoglobin promoter in vivo.  
 
This study also determined the SUMOylation status of LXRs in suppressing the 
hepatic APR. Evidence from Lxra and Lxrb null mice confirmed that transrepression 
of the haptoglobin gene in liver was LXRβ-specific. Further, it was shown that LXRβ 
co-occupied the promoter with HDAC4 and SUMO-2/3. Accordingly, no significant 
differences were detected regarding the recruitment of LXRs onto the haptoglobin 
promoter in the liver of Sumo1 null mice, providing support for the specificity of 
SUMO-1 and LRH-1. However, GPS2 was shown to mediate NR-, ligand- and 
SUMOylation-dependent interaction of both LXRβ and LRH-1 in liver. It remains to 
be determined whether GPS2 is the universal SUMO-NR sensor of the transrepression 
complex or whether each tissue has their specific mechanisms. In macrophages, GPS2 
was not detected on Nos2 or Il1b promoters, although LXRs were present, suggesting 
that other mechanisms exist (Huang et al. 2011). 
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Figure 9. Inflammatory response of Sumo1 null mice upon LPS treatment for 6 h. A. 
Serum levels of TNF?? B–D. mRNA levels of Tnfa (B), Il1b (C) and Nos2 (D) in 
spleen. E–F. Loading of the repressor complex onto the haptoglobin promoter in the 
liver of WT (E) and Sumo1 KO (F) mice. The results are expressed as mean + SEM. 
WT = wild type, KO = Sumo1 knock-out, C = control, LPS = lipopolysaccharide, 
ChIP = chromatin immunoprecipitation 
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5. Loss of Sumo1 impairs adipogenesis and activation functions of PPARγ (II, 
IV) 
 
It has been suggested that PPARγ is specifically SUMOylated by SUMO-1 in 
transrepression (Ghisletti et al. 2007). As PPARγ is the master regulator of adipose 
tissue and the protein indispensable for adipogenesis directly regulating many genes 
involved in the adipogenic program (Rosen et al. 1999; Nielsen et al. 2008), the 
ability of Sumo1 null MEFs to differentiate into adipocytes was studied. Surprisingly, 
no difference was observed between Sumo1 null and WT MEFs as measured by Oil 
Red O staining of the adipocytes and by qPCR analysis of expression of adipocyte 
marker genes, Pparg or aP2, after a 8-day differentiation protocol. However, when a 
longer adipogenic protocol (12 days) was used, there was a clear inhibition of 
adipogenesis in the absence of SUMO-1, as judged by Oil Red O staining of lipids 
and expression of four adipocyte marker genes, aP2, Pparg, Adipoq and Lpl, 
suggesting that lack of SUMOylation attenuates terminal differentiation of adipocytes 
more than early adipogenesis (Fig. 10A-B, II, IV). As was noted previously in MEFs 
and testes (II), Sumo2 or Sumo3 mRNA levels were not up-regulated in Sumo1 KO 
cells, leaving the possibility that there may be some compensation between the 
paralogs at the protein level. Since the efficiency of adipocyte differentiation using 
MEFs was quite low, the results were repeated using bone marrow MSCs of Sumo1 
null and WT mice. To study the mechanisms further in a well-established model 
system, a SUMO-1-depleted 3T3-L1 cell line was created by using lentivirus-
mediated expression of shRNA to target Sumo1 mRNA, and a cell line with a Sumo1 
mRNA depletion of ~80% was chosen for subsequent experiments. Expectedly, the 
control cells differentiated into adipocytes more efficiently than SUMO-1-depleted 
3T3-L1 cells, showing a 50% reduction in aP2 mRNA level. Collectively, these 
results from MEFs, MSCs and 3T3-L1 cells confirmed that SUMO-1 function is 
important for adipogenesis. Another group has shown that knock-down of Ubc9 in 
3T3-L1 cells also results in diminished adipogenic efficiency (Cignarelli et al. 2010). 
However, as UBC9 is the E2 enzyme for all SUMO paralogs, it is possible that lower 
levels of overall SUMOylation affect multiple cellular functions and cell viability. 
There is also evidence that deSUMOylation is important for adipogenesis, as SENP2 
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was found essential for adipogenesis and maintenance of C/EBPβ levels (Chung et al. 
2010). 
 
 
 
 
 
 
Figure 10. Adipogenesis from WT and Sumo1 null MEFs. A. Oil Red O staining of 
adipocytes and their quantification. B and C. mRNA levels of two adipocyte markers, 
aP2 and Pparg. 
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expression of PPARγ target genes, Plin1 and Fsp27, was studied and found to be 
lower in Sumo1 null than WT adipocytes differentiated from MEFs, in addition to 
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where it, together with C/EBPα, upregulates its own expression levels (Wu et al. 
1999). Since PPARγ1 and PPARγ2 protein levels were also lower in mature 
adipocytes differentiated from Sumo1 null than from WT MEFs, this could partly 
explain the attenuated expression of PPARγ target genes. To circumvent this potential 
caveat, PPARγ protein was transiently expressed together with a PPARγ response 
element (PPRE) reporter in immortalized Sumo1 null and WT MEFs. Transactivation 
of the reporter gene by PPARγ was significantly attenuated in Sumo1 null MEFs 
compared to WT MEFs, indicating that SUMO-1 is indeed required for optimal 
transactivation function of PPARγ. To assess whether this was related to PPARγ 
binding to chromatin, ChIP assays were used to examine loading of PPARγ onto the 
PPRE of the aP2 promoter in 3T3-L1 cells differentiated into adipocytes. There was 
no difference in the loading of PPARγ onto the aP2 promoter between control and 
SUMO-1-depleted 3T3-L1 cells, despite the fact that aP2 mRNA levels were 
decreased in SUMO-1-depleted cells and the PPARγ levels did not differ.  
 
MEFs require the presence of PPARγ agonist for efficient adipogenesis. To assess the 
responsiveness of the cells to agonist treatment, rosiglitazone was omitted from the 
MEF adipocyte differentiation medium after four days to be reintroduced after a five-
day pause. In control cells, with no rosiglitazone, aP2 mRNA levels did not differ 
between KO and WT MEFs. However, when rosiglitazone was reintroduced, aP2 
mRNA accumulation was significantly higher in WT than in Sumo1 null MEFs (Fig. 
11A). These results in cultured cells suggested that the function of ligand-occupied 
PPARγ is attenuated in the absence of SUMO-1. To test this in vivo, Sumo1 null mice 
and their WT littermates were treated with rosiglitazone (10 mg/kg). Increased Ucp1 
mRNA accumulation was clearly observed after the 13-day rosiglitazone treatment in 
BAT of WT mice but not of KO mice, and a similar trend was seen in WAT (Fig. 
11B). The treatment also brought about a significant increase in Sumo1 mRNA level 
in WT BAT but, interestingly, not in WAT.  
 
The finding that the transactivation function of PPARγ and responses to agonist 
treatment required SUMO-1 both in vitro and in vivo was not predictable, since 
mutation of the SUMOylation site has been reported to activate PPARγ function in 
vitro (Hu et al. 1996; Ohshima et al. 2004; Yamashita et al. 2004; Floyd and Stephens 
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2004). By and large, SUMOylation of NRs has been associated with repression of the 
NR function (Pourcet et al. 2010; Poukka et al. 2000; Sentis et al. 2005). However, in 
thyroid hormone receptor (TR) function, SUMO-1 is required for ligand-induced 
recruitment of the co-activator CREB-binding protein (CBP) and release of nuclear 
receptor co-repressor (NCoR) on a response element, but SUMOylation had no 
significant effect on TR DNA binding (Liu et al. 2012c). It is likely that SUMO-1 
requirement for turning on aP2 expression (and possibly that of other genes) is not 
related to the SUMOylation of PPARγ itself, but is needed for binding of a 
coactivator or exclusion of a corepressor. Furthermore, it is important to study each 
promoter in each cell type separately before drawing generalized conclusions. 
Genome-wide techniques will be essential in determining the binding sites of PPARγ 
and its coregulators under SUMO-less conditions to examine whether the mechanism 
determined at the aP2 promoter apply to other sites as well.  
 
 
Figure 11. PPAR? ligand responsiveness in the absence of SUMO-1 A. Effects of 
rosiglitazone on adipocyte differentiation of MEFs. After four days of differentiation, 
rosiglitazone was omitted from the medium for five days and reintroduced for two 
days. aP2 mRNA levels were measured with qPCR. B. WT and Sumo1 null mice 
were treated with rosiglitazone. Expression of Ucp1, a PPAR? target gene, was 
measured from WAT and BAT. WT = wild type, KO = Sumo1 knock-out, AC = 
adipocyte, WAT = white adipose tissue, BAT = brown adipose tissue, * = p < 0.05 
WT rosiglitazone vs. WT vehicle. 
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6. Sumo1 null mice are protected from obesity on high-fat diet (IV) 
 
As SUMO-1 was shown to play a role in adipogenesis in vitro and rosiglitazone 
treatment of Sumo1 null mice suggested that activation functions of PPARγ would be 
SUMO-1-specific in vivo, Sumo1 null mice were subjected to high-fat diet (HFD). 
HFD normally results in weight gain and expansion of WAT, both thought to require 
PPARγ activity, as adipose tissue expansion and weight gain are major side-effects in 
patients receiving rosiglitazone treatment (Cariou et al. 2012). The HFD, containing 
60% of the calories from fat, was found to result in lower weight-gain in KO than WT 
mice, both in males and females (Fig. 12A and IV). MRI studies indicated that this 
weight-gain was due to limited accumulation of WAT in the KO mice, whereas the 
lean mass did not differ between the phenotypes. Sumo1 null mice consumed a 
smaller amount of food per mouse than WT mice. However, this cannot explain the 
phenotype entirely, as the food consumption normalized to body weight did not differ 
between KO and WT mice.  
 
Weight gain is dependent on calorie consumption, food absorption, and burning of the 
calories. There was no difference in fat absorption from the gut, as judged by a similar 
fecal fat content in WT and Sumo1 null mice. BAT depots were therefore examined 
more carefully, as BAT is a specialized tissue where the respiratory chain is partially 
uncoupled from ATP production by uncoupling proteins (UCPs) thus generating heat. 
However, BAT appeared indistinguishable between the two phenotypes 
histologically, the weight of the interscapular BAT depots was similar, and the 
expression of Ucp1 or Pgc1α did not differ between the two phenotypes. Sumo1 null 
and WT mice showed no difference in rectal temperature, implying that their overall 
BAT functions were not significantly different.  
 
In obesity, WAT expands both by hypertrophy and hyperplasia. When the capacity of 
the WAT to store FA reaches its limit, the tissue starts to secrete inflammatory 
signals, which causes whole body insulin resistance. The gonadal fat pad was chosen 
for closer examination, because it represents metabolically relevant visceral fat 
depots. Gonadal fat consists mainly of white adipocytes and is not easily converted 
into beige cells, brown-like adipocytes that have been shown to emerge from inguinal 
white adipose tissue (Fisher et al. 2012). There was a significantly decreased amount 
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of DNA in fad pads of Sumo1 null mice on HFD, reflecting a reduced adipocyte 
number. The amount of DNA in fat pads on control diet was similar between the two 
phenotypes, suggesting that the expansion of the depot was disturbed in KO mice 
(Fig. 12B). The adipocytes in the gonadal fat depot were also smaller in Sumo1 KO 
than WT mice on HFD (Fig. 12C), implying that both hyperplasia and hypertrophy 
are dysregulated in the Sumo1 null mice. Taken together, the results obtained from the 
HFD experiments confirm that the disturbances in adipogenesis seen in Sumo1 
depleted cells also apply to in vivo conditions by preventing the expansion of WAT in 
obesity.  
 
 
 
 
 
Figure 12. WT and Sumo1 null mice on HFD. A. Weight gain. B. Quantification of 
DNA from gonadal WAT. C. Histology of WAT. WT = wild-type, KO = Sumo1 null, 
HFD = high-fat diet. 
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The HFD experiments were carried out with mice lacking SUMO-1 in all tissues at all 
times. Therefore, it is possible that some of the consequences detected in WAT are 
modulated by other tissues or are due to developmental defects. It has been shown 
that many outcomes of TZD treatment are due to PPARγ action in brain (Lu et al. 
2012), which may as well be affected by the lack of SUMO-1, but this phenomenon 
not explored in the present study. Furthermore, since inflammation accounts for many 
of the adverse effects of the metabolic syndrome and aggravates insulin resistance, the 
inflammatory status of WAT and other tissues is likely to add one more piece to the 
complex puzzle pertaining to the effects of SUMO-1 in metabolism. 
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FUTURE PERSPECTIVES 
 
 
This study established SUMOylation as an essential modulator of the in vivo 
responses to inflammation and obesity, and maintenance of normal testicular 
architecture. The thesis work used two knock-out mouse lines, lacking Sumo1 or 
Pias2 from all cells of the body at all developmental stages. The gene-targeted mice 
were viable and fertile, although specific functions for each gene was found in this 
study, that is, PIAS2 is required for normal testicular volume and SUMO-1 is a 
regulator of LRH-1 in liver upon LPS-induced inflammation and of PPARγ in WAT 
on HFD and adipogenesis. As SUMOylation is indispensable for life, the different 
members of the SUMO pathway must exhibit significant redundancy in most 
functions. It is also important to note that the PIAS proteins function not only as E3 
enzymes but also as regulators of STAT signaling, implying that some of the effects 
of knocking out PIAS proteins may not be linked to SUMOylation. Therefore, more 
in vivo studies using different knock-out combinations are needed to find out the 
specific functions of each gene. Also, knock-in mouse models expressing 
unSUMOylatable forms of different SUMO targets – such as PPARγ and LRH-1 – 
will be needed. 
 
Obesity is a complex phenomenon that integrates metabolic and inflammatory 
responses in several tissues, including adipose tissue, liver, muscle and macrophages. 
It will be interesting, in the future, to specify the functions of SUMO-1 in inducible 
knock-out mice by turning the expression off in different tissues. Sumo1 knock-out 
mice showed resistance to HFD-induced obesity, but nevertheless exhibited decreased 
glucose tolerance, to a level comparable to that of WT mice. Therefore, a drug that 
targets SUMO in all tissues is expected to have no benefit in treating the adverse 
metabolic effects of obesity. However, tissue-specific mechanisms may provide more 
possibilities in the future, as preventing the SUMOylation in adipose tissue alone 
could be beneficial in treating obesity without increasing the inflammation in 
macrophages and liver.  
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The in vivo functions of SUMO-2 and SUMO-3 are still largely unknown, although 
there is evidence that both are involved in stress responses (Tempé et al. 2008). 
Currently, the two proteins have been largely referred to as SUMO-2/3 due to the lack 
of paralog-specific antibodies. Animal models lacking SUMO-2 or SUMO-3 have not 
yet been described, but will hopefully provide many answers concerning the paralog 
selectivity. Our laboratory made an effort to produce a Sumo2 knock-out mouse line 
using different gene trap ESCs, but all attempts resulted in a failure of the chimeric 
mice to transfer the gene trap to their progeny, suggesting that SUMO-2 is important 
for haploid sperm cells and their ability to fertilize an egg. However, ESCs have to be 
carefully kept in undifferentiated form before the morula aggregation, leaving the 
possibility of a technical problem. In addition, as the gene trap construct is randomly 
integrated into the ESC genome, disruption of another gene by a second integration 
event has to be excluded. Preliminary results from Sumo3 knock-out mice generated 
by the gene trap method in our laboratory suggest a partial embryonic lethality. It 
seems, therefore, that evolution has had its reasons to maintain two nearly identical 
genes, an explanation for this is still to be discovered. 
Summary and conclusions 
 76 
SUMMARY AND CONCLUSIONS 
 
SUMOylation is a conserved post-translational modification system present from 
yeast to humans. Mammals have three functional Sumo genes and a selection of 
SUMOylation enzymes. This study aimed at determining the in vivo functions of 
SUMOylation under normal conditions, in inflammation and on high-fat diet. The 
main conclusions can be summarized as follows: 
 
• Disruption of the Pias2 gene in mice results in a reduced testis weight and 
epididymal sperm count. However, normal fertility is maintained without 
compensatory increases in the expression of the other Pias genes. 
 
• Sumo1 null mice are viable, fertile and indistinguishable from wild-type mice 
under normal conditions for laboratory animals. The lack of SUMO-1 can be 
compensated for by SUMO-2 and SUMO-3 proteins, which are abundantly, 
present in the unconjugated form. 
 
• Sumo1 null mice exhibit a pronounced acute phase response upon LPS 
stimulation due to inefficient loading of LRH-1 onto inflammatory gene 
promoters. This result expands the role of SUMOylation in transrepression 
and shows a SUMO-1-specific effect in vivo. 
 
• Lack of Sumo1 results in impaired terminal adipogenesis via diminished 
activation functions of PPARγ, the master regulator of adipose tissue. These 
PPARγ functions require SUMO-1 in vivo as well, as rosiglitazone fails to 
activate PPARγ target genes in adipose tissue of Sumo1 null mice. 
 
• Sumo1 null mice are resistant to high-fat diet-induced obesity due to 
inefficient expandability of their white adipose tissue (WAT), highlighted by 
the presence of smaller and fewer adipocytes. This has no effect on glucose 
tolerance but reduces the inflammation of their WAT.  
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